Salicylates	O
inhibit	O
lipopolysaccharide-induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Binding	O
of	O
plasma	B-protein
Factor	I-protein
VII/VIIa	I-protein
to	O
the	O
tissue	B-protein
factor	I-protein
(	I-protein
TF	I-protein
)	I-protein
receptor	I-protein
initiates	O
the	O
coagulation	B-protein
protease	I-protein
cascades	O
.	O

TF	O
expression	O
by	O
circulating	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	B-DNA
TF	I-DNA
gene	I-DNA
in	O
monocytic	B-cell_type
cells	I-cell_type
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
TF	B-DNA
promoter	I-DNA
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti-inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS-induced	O
proteolytic	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
preventing	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Salicylates	NULL
Inhibit	NULL
Lipopolysaccharide-Induced	NULL
Transcriptional	NULL
Activation	NULL
of	NULL
the	NULL
Tissue	NULL
Factor	NULL
Gene	NULL
in	NULL
Human	NULL
Monocytic	NULL
Cells	NULL
By	NULL
Paul	NULL
Oeth	NULL
and	NULL
Nige	NULL
!	NULL

Mackman	NULL
Binding	NULL
of	NULL
plasma	NULL
Factor	NULL
VIl/Vila	NULL
to	NULL
the	NULL
tissue	NULL
factor	NULL
(	NULL
TF	NULL
)	NULL
receptor	NULL
initiates	NULL
the	NULL
coagulation	NULL
protease	NULL
cascades	NULL
.	NULL

TF	NULL
expression	NULL
by	NULL
circulating	NULL
monocytes	NULL
is	NULL
associated	NULL
with	NULL
throm-botic	NULL
and	NULL
inflammatory	NULL
complications	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
dis-eases	NULL
.	NULL

Transcriptional	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
TF	NULL
gene	NULL
in	NULL
monocytic	NULL
cells	NULL
exposed	NULL
to	NULL
bacterial	NULL
lipopolysaccharide	NULL
{	NULL
(	NULL
LPS	NULL
)	NULL
is	NULL
mediated	NULL
by	NULL
binding	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
to	NULL
a	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
TF	NULL
promoter	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
report	NULL
that	NULL
a	NULL
family	NULL
of	NULL
anti-inflammatory	NULL
agents	NULL
,	NULL
known	NULL
as	NULL
the	NULL
salicylates	NULL
,	NULL
inhibited	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
activity	NULL
and	NULL
TF	NULL
gene	NULL
transcription	NULL
in	NULL
human	NULL
monocytes	NULL
and	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
at	NULL
clinically	NULL
relevant	NULL
doses	NULL
.	NULL

Furthermore	NULL
,	NULL
sodium	NULL
salicylate	NULL
blocked	NULL
the	NULL
ISSUE	NULL
FACTOR	NULL
(	NULL
TF	NULL
)	NULL
EXPRESSION	NULL
initiates	NULL
the	NULL
coagulation	NULL
protease	NULL
cascades	NULL
,	NULL
which	NULL
generates	NULL
thrombin	NULL
and	NULL
leads	NULL
to	NULL
fibrin	NULL
deposition	NULL
.	NULL
``	NULL

Aberrant	NULL
expression	NULL
of	NULL
TF	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
clinical	NULL
disorders	NULL
such	NULL
as	NULL
atherosclerosis	NULL
,	NULL
``	NULL
rheumatoid	NULL
arthritis	NULL
,	NULL
Gram-negative	NULL
sep-sis	NULL
,	NULL
``	NULL
and	NULL
various	NULL
forms	NULL
of	NULL
cancer	NULL
.	NULL
``	NULL

''	NULL
In	NULL
Gram-negative	NULL
sepsis	NULL
,	NULL
endotoxin-induced	NULL
activation	NULL
of	NULL
blood	NULL
coagulation	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
development	NULL
of	NULL
multiple	NULL
organ	NULL
failure	NULL
by	NULL
triggering	NULL
disseminated	NULL
intravascular	NULL
coagulation	NULL
.	NULL
'	NULL

''	NULL
In	NULL
rab-bits	NULL
,	NULL
disseminated	NULL
intravascular	NULL
coagulation	NULL
is	NULL
manifested	NULL
by	NULL
administration	NULL
of	NULL
TF	NULL
or	NULL
endotoxin	NULL
and	NULL
is	NULL
blocked	NULL
by	NULL
treatment	NULL
of	NULL
the	NULL
animals	NULL
with	NULL
anti-TF	NULL
antibodies	NULL
.	NULL
``	NULL

In	NULL
a	NULL
baboon	NULL
model	NULL
of	NULL
lethal	NULL
septic	NULL
shock	NULL
,	NULL
an	NULL
antihuman	NULL
TF	NULL
monoclonal	NULL
antibody	NULL
prevented	NULL
coagulopathy	NULL
and	NULL
protected	NULL
against	NULL
le-thality	NULL
,	NULL
``	NULL
suggesting	NULL
that	NULL
TF	NULL
plays	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
the	NULL
pathology	NULL
of	NULL
this	NULL
disease	NULL
.	NULL

Monocytes	NULL
are	NULL
the	NULL
only	NULL
circulating	NULL
cell	NULL
type	NULL
that	NULL
can	NULL
express	NULL
TF	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
cells	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
primary	NULL
source	NULL
of	NULL
TF	NULL
expression	NULL
in	NULL
several	NULL
animal	NULL
models	NULL
of	NULL
sep-sis	NULL
``	NULL
and	NULL
in	NULL
patients	NULL
with	NULL
septicemia	NULL
.	NULL
``	NULL

Pentoxifylline	NULL
,	NULL
an	NULL
agent	NULL
that	NULL
inhibits	NULL
induction	NULL
of	NULL
TF	NULL
expression	NULL
in	NULL
monocytes	NULL
,	NULL
``	NULL
``	NULL
``	NULL
``	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
reduce	NULL
endotoxin-mediated	NULL
coagulation	NULL
in	NULL
chimpanzees	NULL
.	NULL

'*	NULL
Exposure	NULL
of	NULL
monocytes	NULL
to	NULL
bacterial	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
rapidly	NULL
induces	NULL
TF	NULL
gene	NULL
expression	NULL
.	NULL

'*	NULL
``	NULL
*	NULL
Our	NULL
laboratory	NULL
has	NULL
identified	NULL
a	NULL
decameric	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
human	NULL
TF	NULL
promoter	NULL
that	NULL
mediates	NULL
LPS	NULL
induction	NULL
of	NULL
the	NULL
TF	NULL
gene	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
.	NULL
``	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
this	NULL
kB	NULL
site	NULL
exclusively	NULL
binds	NULL
c-Rel/p65	NULL
heterodimers	NULL
that	NULL
are	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
LPS-stimulated	NULL
human	NULL
monocytes	NULL
and	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
.	NULL
``	NULL

Nuclear	NULL
translocation	NULL
of	NULL
these	NULL
c-Rel/p65	NULL
heterodimers	NULL
and	NULL
subsequent	NULL
binding	NULL
From	NULL
the	NULL
Departments	NULL
of	NULL
Immunology	NULL
and	NULL
Vascular	NULL
Biology	NULL
,	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
.	NULL

Submitted	NULL
December	NULL
7	NULL
,	NULL
1994	NULL
;	NULL
accepted	NULL
July	NULL
17	NULL
,	NULL
1995	NULL
.	NULL

Supported	NULL
by	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
No	NULL
.	NULL

HL-48872	NULL
(	NULL
N.M.	NULL
)	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Nigel	NULL
Mackman	NULL
,	NULL
PhD	NULL
,	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
10666	NULL
N	NULL
Torrey	NULL
Pines	NULL
Rd	NULL
,	NULL
IMM	NULL
17	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
92037	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1995	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/95/8611-0003	NULL
$	NULL
3.00/0	NULL
4144	NULL
LPS-induced	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IxBa	NULL
,	NULL
which	NULL
prevented	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
two	NULL
other	NULL
nonsteroidal	NULL
anti-inflammatory	NULL
drugs	NULL
,	NULL
ibuprofen	NULL
and	NULL
indomethacin	NULL
,	NULL
did	NULL
not	NULL
inhibit	NULL
LPS	NULL
induction	NULL
of	NULL
the	NULL
TF	NULL
gene	NULL
.	NULL

These	NULL
results	NULL
indicated	NULL
that	NULL
salicylates	NULL
inhibited	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
gene	NULL
transcription	NULL
in	NULL
monocytic	NULL
cells	NULL
by	NULL
preventing	NULL
nuclear	NULL
translocation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

The	NULL
clinical	NULL
benefits	NULL
of	NULL
salicylates	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
several	NULL
diseases	NULL
,	NULL
including	NULL
atherosclerosis	NULL
and	NULL
rheumatoid	NULL
arthritis	NULL
,	NULL
may	NULL
be	NULL
related	NULL
to	NULL
their	NULL
ability	NULL
to	NULL
reduce	NULL
monocyte	NULL
gene	NULL
expression	NULL
.	NULL

©	NULL
1995	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

to	NULL
the	NULL
TF	NULL
«	NULL
B	NULL
site	NULL
are	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
TF	NULL
gene	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL
``	NULL

The	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

family	NULL
of	NULL
transcription	NULL
factors	NULL
includes	NULL
p50	NULL
(	NULL
NFKB1	NULL
)	NULL
,	NULL
p52	NULL
(	NULL
NFKB2	NULL
)	NULL
,	NULL
p65	NULL
(	NULL
RelA	NULL
)	NULL
,	NULL
RelB	NULL
,	NULL
v-Rel	NULL
,	NULL
c-Rel	NULL
,	NULL
and	NULL
the	NULL
Drosophila	NULL
maternal	NULL
morphogen	NULL
Dorsal	NULL
.	NULL
``	NULL

Cloning	NULL
of	NULL
the	NULL
genes	NULL
for	NULL
both	NULL
p50	NULL
``	NULL
and	NULL
p65	NULL
``	NULL
revealed	NULL
a	NULL
300-amino	NULL
acid	NULL
region	NULL
which	NULL
showed	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
homology	NULL
to	NULL
a	NULL
region	NULL
in	NULL
the	NULL
proto-oncogene	NULL
product	NULL
c-Rel	NULL
.	NULL
``	NULL

Family	NULL
members	NULL
can	NULL
form	NULL
homodimers	NULL
and	NULL
heterodimers	NULL
,	NULL
``	NULL
and	NULL
different	NULL
«	NULL
B	NULL
sites	NULL
selectively	NULL
bind	NULL
these	NULL
transcription	NULL
factors	NULL
.	NULL
``	NULL

''	NULL
For	NULL
example	NULL
,	NULL
the	NULL
TF	NULL
gene	NULL
is	NULL
specifically	NULL
regulated	NULL
by	NULL
a	NULL
decameric	NULL
KB	NULL
site	NULL
that	NULL
binds	NULL
c-Rel/p65	NULL
heterodimers	NULL
,	NULL
``	NULL
whereas	NULL
expression	NULL
of	NULL
many	NULL
other	NULL
genes	NULL
that	NULL
are	NULL
inducibly	NULL
expressed	NULL
in	NULL
monocytes	NULL
is	NULL
regulated	NULL
by	NULL
p50/p65	NULL
heterodimers	NULL
.	NULL
``	NULL

NF-	NULL
«	NULL
B/Rel	NULL
family	NULL
members	NULL
are	NULL
retained	NULL
in	NULL
the	NULL
cytosol	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
a	NULL
group	NULL
of	NULL
inhibitor	NULL
proteins	NULL
,	NULL
including	NULL
I	NULL
«	NULL
kBa	NULL
.	NULL
``	NULL

Proteolytic	NULL
degradation	NULL
of	NULL
IxBa	NULL
is	NULL
required	NULL
for	NULL
activation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
p50/p65	NULL
and	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

Salicylic	NULL
acid	NULL
and	NULL
its	NULL
derivatives	NULL
,	NULL
commonly	NULL
termed	NULL
the	NULL
salicylates	NULL
,	NULL
are	NULL
a	NULL
class	NULL
of	NULL
nonsteroidal	NULL
anti-inflammatory	NULL
drugs	NULL
(	NULL
NSAIDs	NULL
)	NULL
administered	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
many	NULL
dis-eases	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
The	NULL
acetylated	NULL
form	NULL
of	NULL
salicylic	NULL
acid	NULL
,	NULL
acetylsalicylic	NULL
acid	NULL
(	NULL
commonly	NULL
known	NULL
as	NULL
aspirin	NULL
)	NULL
,	NULL
is	NULL
the	NULL
most	NULL
widely	NULL
used	NULL
member	NULL
of	NULL
the	NULL
salicylates	NULL
,	NULL
which	NULL
also	NULL
include	NULL
sodium	NULL
salicylate	NULL
(	NULL
NaSal	NULL
)	NULL
,	NULL
salsalate	NULL
,	NULL
diffunisal	NULL
,	NULL
and	NULL
fendosal	NULL
.	NULL
``	NULL

'	NULL
The	NULL
effectiveness	NULL
of	NULL
low	NULL
doses	NULL
of	NULL
aspirin	NULL
to	NULL
reduce	NULL
inflammation	NULL
is	NULL
due	NULL
,	NULL
in	NULL
part	NULL
,	NULL
to	NULL
its	NULL
ability	NULL
to	NULL
inhibit	NULL
the	NULL
synthesis	NULL
and	NULL
release	NULL
of	NULL
prostaglandins	NULL
by	NULL
strictly	NULL
limiting	NULL
production	NULL
of	NULL
the	NULL
cyclooxygenase	NULL
prostaglandin	NULL
H	NULL
synthase	NULL
.	NULL
``	NULL

'	NULL
However	NULL
,	NULL
nonacetylated	NULL
salicylates	NULL
do	NULL
not	NULL
interfere	NULL
with	NULL
prostaglandin	NULL
synthesis	NULL
``	NULL
but	NULL
are	NULL
still	NULL
effective	NULL
anti-inflammatory	NULL
agents	NULL
when	NULL
used	NULL
at	NULL
high	NULL
doses	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
diseases	NULL
such	NULL
as	NULL
rheumatoid	NULL
arthritis	NULL
,	NULL
``	NULL
``	NULL
``	NULL
suggesting	NULL
that	NULL
salicylates	NULL
may	NULL
reduce	NULL
inflammation	NULL
by	NULL
other	NULL
mechanisms	NULL
.	NULL

Indeed	NULL
,	NULL
salicylates	NULL
are	NULL
able	NULL
to	NULL
inhibit	NULL
the	NULL
activation	NULL
of	NULL
neutrophils	NULL
and	NULL
prevent	NULL
their	NULL
cell-to-cell	NULL
adhesion	NULL
during	NULL
the	NULL
inflammatory	NULL
process	NULL
.	NULL

``	NULL
``	NULL
**	NULL
``	NULL
``	NULL
More	NULL
recently	NULL
,	NULL
NaSal	NULL
and	NULL
aspirin	NULL
were	NULL
shown	NULL
to	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
human	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
mouse	NULL
pre-B	NULL
cells	NULL
by	NULL
preventing	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IxBa	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
agents	NULL
inhibited	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
,	NULL
presumably	NULL
by	NULL
blocking	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

``	NULL
°	NULL
Thus	NULL
,	NULL
salicylates	NULL
might	NULL
control	NULL
inflammation	NULL
by	NULL
inhibiting	NULL
transcription	NULL
of	NULL
various	NULL
genes	NULL
encoding	NULL
inflammatory	NULL
mediators	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
86	NULL
,	NULL
No	NULL
11	NULL
(	NULL
December	NULL
1	NULL
}	NULL
,	NULL
1995	NULL
:	NULL
pp	NULL
4144-4152	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

SALICYLATES	NULL
INHIBIT	NULL
TISSUE	NULL
FACTOR	NULL
EXPRESSION	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
NaSal	NULL
,	NULL
salsalate	NULL
,	NULL
and	NULL
aspirin	NULL
all	NULL
inhibited	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

All	NULL
three	NULL
agents	NULL
blocked	NULL
LPS-induced	NULL
nuclear	NULL
translocation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
,	NULL
indicating	NULL
that	NULL
they	NULL
inhibited	NULL
TF	NULL
expression	NULL
by	NULL
preventing	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
TF	NULL
gene	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Materials	NULL
.	NULL

-	NULL
LPS	NULL
(	NULL
Escherichia	NULL
coli	NULL
serotype	NULL
O111	NULL
:	NULL
B4	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Calbiochem	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
acetylsalicylic	NULL
acid	NULL
,	NULL
ibuprofen	NULL
,	NULL
and	NULL
indomethacin	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
(	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

NaSal	NULL
and	NULL
salsalate	NULL
were	NULL
purchased	NULL
from	NULL
Aldrich	NULL
Chemical	NULL
(	NULL
Milwaukee	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

A	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-labeled	NULL
conjugate	NULL
of	NULL
MY4	NULL
(	NULL
MY4-FITC	NULL
)	NULL
,	NULL
a	NULL
murine	NULL
monoclonal	NULL
antibody	NULL
to	NULL
human	NULL
CD14	NULL
,	NULL
was	NULL
purchased	NULL
from	NULL
Coulter	NULL
Immunology	NULL
(	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

An	NULL
FITC-labeled	NULL
antihuman	NULL
TF	NULL
antibody	NULL
,	NULL
TF8-5G9	NULL
,	NULL
``	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
TS	NULL
.	NULL

Edgington	NULL
(	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Cell	NULL
viability	NULL
and	NULL
toxicity	NULL
.	NULL

-	NULL
Cell	NULL
viability	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
CellTiter	NULL
96	NULL
Aqueous	NULL
Non-Radioactive	NULL
Cell	NULL
Proliferation	NULL
Assay	NULL
Kit	NULL
(	NULL
Promega	NULL
Corp	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
treated	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
96-well	NULL
plate	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
100	NULL
LL	NULL
.	NULL

A	NULL
total	NULL
of	NULL
20	NULL
LL	NULL
of	NULL
the	NULL
MTS/PMS	NULL
solution	NULL
was	NULL
added	NULL
to	NULL
each	NULL
sample	NULL
,	NULL
and	NULL
the	NULL
plate	NULL
was	NULL
incubated	NULL
at	NULL
37°C	NULL
,	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
for	NULL
5	NULL
hours	NULL
.	NULL

The	NULL
plate	NULL
was	NULL
then	NULL
read	NULL
at	NULL
490	NULL
nm	NULL
on	NULL
an	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
plate	NULL
reader	NULL
(	NULL
Molecular	NULL
De-vices	NULL
,	NULL
Menlo	NULL
Park	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
also	NULL
assessed	NULL
using	NULL
trypan	NULL
blue	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

*S-translabel	NULL
incorporation	NULL
was	NULL
conducted	NULL
as	NULL
follows	NULL
:	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
pelleted	NULL
at	NULL
300g	NULL
for	NULL
15	NULL
minutes	NULL
and	NULL
then	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
media	NULL
without	NULL
cysteine	NULL
or	NULL
methionine	NULL
(	NULL
Bio-Whittaker	NULL
Inc	NULL
,	NULL
Walkersville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
tran	NULL
``	NULL
``	NULL
S	NULL
$	NULL
Metabolic	NULL
Labeling	NULL
Reagent	NULL
(	NULL
ICN	NULL
Pharmaceuticals	NULL
Inc	NULL
,	NULL
Costa	NULL
Mesa	NULL
,	NULL
CA	NULL
)	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
uCi/mL	NULL
.	NULL

After	NULL
treatment	NULL
,	NULL
cells	NULL
were	NULL
pelleted	NULL
at	NULL
300g	NULL
,	NULL
washed	NULL
once	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
100	NULL
4L	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
1	NULL
mg/mL	NULL
)	NULL
.	NULL

Trichloroacetic	NULL
acid-precipitable	NULL
counts	NULL
were	NULL
counted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
mL	NULL
.	NULL

of	NULL
liquid	NULL
scintillant	NULL
(	NULL
Ultima	NULL
Gold	NULL
)	NULL
by	NULL
a	NULL
Beta	NULL
counter	NULL
(	NULL
Beckman	NULL
Instruments	NULL
,	NULL
Irvine	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Monocyte	NULL
isolation	NULL
and	NULL
cell	NULL
culture	NULL
.	NULL

Heparinized	NULL
blood	NULL
was	NULL
drawn	NULL
from	NULL
volunteers	NULL
,	NULL
and	NULL
plasma	NULL
was	NULL
removed	NULL
after	NULL
centrifugation	NULL
at	NULL
200g	NULL
.	NULL

Blood	NULL
cells	NULL
were	NULL
diluted	NULL
1:1	NULL
(	NULL
vol	NULL
:	NULL
vol	NULL
)	NULL
in	NULL
endotoxin-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Inc	NULL
)	NULL
and	NULL
were	NULL
overlaid	NULL
onto	NULL
Ficoll-Hypaque	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
.	NULL

After	NULL
centrifugation	NULL
at	NULL
400g	NULL
,	NULL
the	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
were	NULL
removed	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
medium	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
media	NULL
with	NULL
2	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Gemini	NULL
Bioproducts	NULL
,	NULL
Calaba-sas	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Human	NULL
monocytic	NULL
leukemia	NULL
THP-1	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
were	NULL
cultivated	NULL
at	NULL
a	NULL
density	NULL
of	NULL
2	NULL
to	NULL
5	NULL
x	NULL
10°	NULL
cells/mL	NULL
as	NULL
described	NULL
.	NULL
``	NULL

All	NULL
reagents	NULL
were	NULL
tested	NULL
by	NULL
Limulus	NULL
amebocyte	NULL
lysate	NULL
assay	NULL
(	NULL
Bio-Whittaker	NULL
Inc	NULL
)	NULL
and	NULL
contained	NULL
less	NULL
than	NULL
5	NULL
pg/mL	NULL
endotoxin	NULL
contami-nation	NULL
.	NULL

TF	NULL
activity	NULL
.	NULL

-	NULL
Cell	NULL
pellets	NULL
were	NULL
solubilized	NULL
at	NULL
37°C	NULL
for	NULL
15	NULL
minutes	NULL
using	NULL
15	NULL
mmol/L	NULL
octyl	NULL
3-D-glucopyranoside	NULL
.	NULL

TF	NULL
activity	NULL
was	NULL
assayed	NULL
in	NULL
cell	NULL
lysates	NULL
using	NULL
a	NULL
one-stage	NULL
clotting	NULL
assay	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Clotting	NULL
times	NULL
were	NULL
converted	NULL
to	NULL
milliunits	NULL
of	NULL
TF	NULL
activity	NULL
by	NULL
comparison	NULL
with	NULL
a	NULL
standard	NULL
curve	NULL
established	NULL
with	NULL
purified	NULL
human	NULL
brain	NULL
TF	NULL
.	NULL
``	NULL

For	NULL
reference	NULL
,	NULL
a	NULL
clotting	NULL
time	NULL
of	NULL
50	NULL
seconds	NULL
corresponds	NULL
to	NULL
1,000	NULL
mU	NULL
of	NULL
TF	NULL
activity	NULL
.	NULL

Fluorescence	NULL
activated	NULL
cell	NULL
sorting	NULL
(	NULL
FACS	NULL
)	NULL
.	NULL

-	NULL
PBMCs	NULL
(	NULL
1	NULL
x	NULL
10°	NULL
cells/mL	NULL
)	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
hours	NULL
with	NULL
10	NULL
ng/mL	NULL
LPS	NULL
before	NULL
incubation	NULL
of	NULL
cells	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
4°C	NULL
with	NULL
antibuman	NULL
TF-FITC	NULL
or	NULL
MY4-FITC	NULL
antibodies	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
fixed	NULL
in	NULL
0.5	NULL
%	NULL
paraformal-dehyde	NULL
and	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
a	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Live	NULL
gating	NULL
on	NULL
the	NULL
monocyte	NULL
4145	NULL
population	NULL
was	NULL
accomplished	NULL
using	NULL
near	NULL
forward	NULL
angle	NULL
and	NULL
orthogonal	NULL
light	NULL
scatter	NULL
as	NULL
well	NULL
as	NULL
staining	NULL
with	NULL
MY4-FITC	NULL
antibody	NULL
.	NULL

Analysis	NULL
of	NULL
TF	NULL
mRNA	NULL
.	NULL

-	NULL
Total	NULL
cellular	NULL
RNA	NULL
,	NULL
purified	NULL
using	NULL
TRL-ZOL	NULL
reagent	NULL
(	NULL
GIBCO-BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
was	NULL
analyzed	NULL
by	NULL
Northern	NULL
blotting	NULL
as	NULL
described	NULL
.	NULL
``	NULL

A	NULL
641-bp	NULL
human	NULL
TF	NULL
cDNA	NULL
frag-ment	NULL
``	NULL
was	NULL
labeled	NULL
with	NULL
[	NULL
aP	NULL
]	NULL
deoxycytidine	NULL
triphosphate	NULL
(	NULL
ICN	NULL
)	NULL
using	NULL
the	NULL
Prime-It	NULL
Kit	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
was	NULL
used	NULL
to	NULL
determine	NULL
TF	NULL
mRNA	NULL
levels	NULL
.	NULL

An	NULL
egr-1	NULL
cDNA	NULL
fragment	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
E.	NULL
Adamson	NULL
(	NULL
La	NULL
Jolla	NULL
Cancer	NULL
Research	NULL
Foundation	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Blots	NULL
were	NULL
rehybridized	NULL
with	NULL
the	NULL
housekeeping	NULL
genes	NULL
,	NULL
glucose-6-phosphate	NULL
dehydrogenase	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
G.	NULL
Parry	NULL
,	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
)	NULL
or	NULL
glyceraldehyde	NULL
3-phosphate	NULL
dehydrogenase	NULL
(	NULL
G3PDH	NULL
;	NULL
Clontech	NULL
Laboratories	NULL
,	NULL
Inc	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Auto-radiography	NULL
was	NULL
performed	NULL
at	NULL
-70°C	NULL
,	NULL
using	NULL
Kodak	NULL
XAR-5	NULL
film	NULL
with	NULL
intensifying	NULL
screens	NULL
(	NULL
Eastman-Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Band	NULL
intensites	NULL
were	NULL
quantified	NULL
by	NULL
densitometric	NULL
analysis	NULL
using	NULL
a	NULL
Phosphoimager	NULL
and	NULL
ImageQuant	NULL
software	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sun-nyvale	NULL
,	NULL
CA	NULL
)	NULL
or	NULL
Personal	NULL
Densitometer	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

Nuclear	NULL
run-on	NULL
.	NULL

-	NULL
Nuclear	NULL
run-on	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
a	NULL
modification	NULL
of	NULL
a	NULL
procedure	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

Cells	NULL
were	NULL
unstimulated	NULL
or	NULL
LPS	NULL
(	NULL
10	NULL
ug/mL	NULL
)	NULL
-stimulated	NULL
(	NULL
for	NULL
1	NULL
hour	NULL
)	NULL
with	NULL
or	NULL
without	NULL
a	NULL
15-minute	NULL
pretreatment	NULL
with	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
.	NULL

Cells	NULL
(	NULL
5	NULL
x	NULL
10	NULL
``	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
a	NULL
homogenizer	NULL
and	NULL
nuclei	NULL
were	NULL
collected	NULL
using	NULL
a	NULL
sucrose	NULL
(	NULL
2.0	NULL
mol/L	NULL
)	NULL
cushion	NULL
.	NULL

Nuclear	NULL
RNA	NULL
was	NULL
labeled	NULL
using	NULL
[	NULL
a-	NULL
``	NULL
P	NULL
]	NULL
uridine	NULL
triphosphate	NULL
(	NULL
UTP	NULL
)	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
treated	NULL
sequentially	NULL
with	NULL
DNase	NULL
I	NULL
(	NULL
final	NULL
concentration	NULL
,	NULL
1	NULL
U/uL	NULL
)	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
37°C	NULL
and	NULL
with	NULL
proteinase	NULL
K	NULL
(	NULL
final	NULL
concentration	NULL
,	NULL
200	NULL
ug/mL	NULL
)	NULL
for	NULL
45	NULL
PBMC	NULL
200	NULL
§	NULL
THP	NULL
|	NULL
(	NULL
mU/10°	NULL
cells	NULL
)	NULL
pS	NULL
}	NULL
8	NULL
o	NULL
Tissue	NULL
Factor	NULL
Activi	NULL
a	NULL
s	NULL
50	NULL
0	NULL
LPS	NULL
=	NULL
+	NULL
NSAID	NULL
|	NULL
-	NULL
a	NULL
NaSal	NULL
+	NULL
Salsalate	NULL
+	NULL
Aspirin	NULL
+	NULL
Ibuprofen	NULL
+	NULL
Indomethacin	NULL
+	NULL
Fig	NULL
1	NULL
.	NULL

Effects	NULL
of	NULL
various	NULL
NSAIDs	NULL
on	NULL
LPS-induced	NULL
TF	NULL
activity	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
.	NULL

PBMCs	NULL
and	NULL
THP-1	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
LPS	NULL
at	NULL
10	NULL
ng/ml	NULL
or	NULL
10	NULL
mg/mL	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
5	NULL
hours	NULL
with	NULL
or	NULL
without	NULL
a	NULL
15-minute	NULL
pretreatment	NULL
with	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
,	NULL
salsalate	NULL
(	NULL
10	NULL
mmol/L	NULL
}	NULL
,	NULL
aspirin	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
,	NULL
ibuprofen	NULL
(	NULL
200	NULL
pmol/L	NULL
)	NULL
,	NULL
or	NULL
indomethacin	NULL
(	NULL
25	NULL
mol/L	NULL
)	NULL
.	NULL

Control	NULL
samples	NULL
were	NULL
incubated	NULL
for	NULL
5	NULL
hours	NULL
without	NULL
LPS	NULL
or	NULL
any	NULL
NSAIDs	NULL
.	NULL

TF	NULL
activity	NULL
(	NULL
mean	NULL
+	NULL
SD	NULL
)	NULL
is	NULL
shown	NULL
from	NULL
triplicated	NULL
samples	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4146	NULL
350	NULL
soo	NULL
|	NULL
A	NULL
PBMC	NULL
250	NULL
|-2	NULL
200	NULL
|-6	NULL
O	NULL
6	NULL
150	NULL
|-	NULL
[	NULL
=	NULL
]	NULL
S	NULL
100	NULL
|-€	NULL
50	NULL
|-ul	NULL
S	NULL
0	NULL
ral	NULL
3	NULL
-	NULL
200	NULL
4	NULL
-	NULL
1so	NULL
|	NULL
B	NULL
THP	NULL
L3	NULL
o	NULL
-	NULL
160	NULL
|-	NULL
i	NULL
shud	NULL
``	NULL
r	NULL
©	NULL
-	NULL
140	NULL
|-H-	NULL
__	NULL
420	NULL
|	NULL
$	NULL
-	NULL
100	NULL
3	NULL
R	NULL
@	NULL
_	NULL
so	NULL
|-i-	NULL
60	NULL
|-40	NULL
|-20	NULL
|-~	NULL
_.	NULL
o	NULL
22	NULL
e	NULL
LPS	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
NaSal	NULL
(	NULL
mM	NULL
)	NULL
-	NULL
-	NULL
O01	NULL
0.50	NULL
10	NULL
50	NULL
10	NULL
Fig	NULL
2	NULL
.	NULL

-	NULL
NaSal	NULL
inhibition	NULL
of	NULL
LPS-induced	NULL
TF	NULL
activity	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
.	NULL

{	NULL
(	NULL
A	NULL
)	NULL
PBMCs	NULL
were	NULL
exposed	NULL
to	NULL
LPS	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
for	NULL
5	NULL
hours	NULL
with	NULL
or	NULL
without	NULL
a	NULL
15-minute	NULL
pretreatment	NULL
with	NULL
NaSal	NULL
at	NULL
doses	NULL
ranging	NULL
from	NULL
0.1	NULL
to	NULL
10	NULL
mmol/L	NULL
.	NULL

(	NULL
B	NULL
)	NULL
THP-1	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
LPS	NULL
{	NULL
10	NULL
g/mL	NULL
)	NULL
for	NULL
5	NULL
hours	NULL
with	NULL
or	NULL
without	NULL
a	NULL
15-minute	NULL
pretreatment	NULL
with	NULL
NaSal	NULL
at	NULL
doses	NULL
ranging	NULL
from	NULL
0.1	NULL
to	NULL
10	NULL
mmol/L	NULL
.	NULL

Control	NULL
samples	NULL
were	NULL
incubated	NULL
for	NULL
5	NULL
hours	NULL
without	NULL
LPS	NULL
or	NULL
NaSal	NULL
.	NULL

TF	NULL
activity	NULL
(	NULL
mean	NULL
+	NULL
SD	NULL
)	NULL
is	NULL
shown	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

minutes	NULL
at	NULL
37°C	NULL
.	NULL

Samples	NULL
were	NULL
extracted	NULL
with	NULL
phenol/chloroform	NULL
and	NULL
were	NULL
ethanol-precipitated	NULL
,	NULL
and	NULL
nuclear	NULL
RNA	NULL
was	NULL
purified	NULL
using	NULL
a	NULL
G-50	NULL
column	NULL
.	NULL

Prehybridization	NULL
,	NULL
hybridization	NULL
,	NULL
and	NULL
washing	NULL
of	NULL
the	NULL
filters	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
.	NULL
``	NULL

''	NULL
Radioactivity	NULL
was	NULL
quantified	NULL
using	NULL
a	NULL
Phosphoimager	NULL
and	NULL
ImageQuant	NULL
software	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

Plasmids	NULL
and	NULL
transfections	NULL
.	NULL

-	NULL
TF	NULL
,	NULL
G3PDH	NULL
and	NULL
tumor	NULL
necrosis	NULL
fac-tor-a	NULL
(	NULL
TNFa	NULL
)	NULL
cDNAs	NULL
present	NULL
in	NULL
pGEM3Z	NULL
(	NULL
Promega	NULL
Corp	NULL
)	NULL
,	NULL
pSP73	NULL
(	NULL
Promega	NULL
Corp	NULL
)	NULL
,	NULL
and	NULL
pSP64	NULL
,	NULL
``	NULL
°	NULL
respectively	NULL
,	NULL
were	NULL
used	NULL
in	NULL
the	NULL
nuclear	NULL
run-on	NULL
assays	NULL
.	NULL

pTF	NULL
(	NULL
-278	NULL
)	NULL
LUC	NULL
contains	NULL
278	NULL
bp	NULL
of	NULL
the	NULL
human	NULL
TF	NULL
promoter	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
``	NULL
and	NULL
p	NULL
(	NULL
TF	NULL
)	NULL
,	NULL
SVLUC	NULL
contains	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
TF	NULL
«	NULL
B	NULL
site	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
promoter	NULL
encoding	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
.	NULL
``	NULL

'	NULL
Cells	NULL
were	NULL
transfected	NULL
using	NULL
diethyl	NULL
aminoethyl-dex-tran	NULL
``	NULL
``	NULL
and	NULL
were	NULL
cultivated	NULL
for	NULL
46	NULL
hours	NULL
before	NULL
a	NULL
5-hour	NULL
stimulation	NULL
with	NULL
LPS	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
Luciferase	NULL
Assay	NULL
System	NULL
(	NULL
Promega	NULL
Corp	NULL
)	NULL
and	NULL
Monolight	NULL
2010	NULL
luminometer	NULL
(	NULL
Analytical	NULL
Luminescence	NULL
Inc	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

A	NULL
total	NULL
of	NULL
2	NULL
ug	NULL
of	NULL
pRSVCAT	NULL
was	NULL
used	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
to	NULL
assess	NULL
transfection	NULL
efficiencies	NULL
.	NULL

Chloramphenicol	NULL
acetyl	NULL
transferase	NULL
activity	NULL
expressed	NULL
by	NULL
pRSVCAT	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
diffusion-based	NULL
assay	NULL
``	NULL
and	NULL
showed	NULL
less	NULL
than	NULL
a	NULL
10	NULL
%	NULL
variation	NULL
between	NULL
samples	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

-	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Protein	NULL
concentrations	NULL
in	NULL
these	NULL
extracts	NULL
were	NULL
1	NULL
to	NULL
5	NULL
mg/mL	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
BCA	NULL
OETH	NULL
AND	NULL
MACKMAN	NULL
protein	NULL
assay	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

An	NULL
oligonucleotide	NULL
(	NULL
Operon	NULL
Technologies	NULL
Inc	NULL
,	NULL
Alameda	NULL
,	NULL
CA	NULL
)	NULL
containing	NULL
the	NULL
TF	NULL
xB	NULL
site	NULL
(	NULL
underlined	NULL
)	NULL
,	NULL
5-GTCCCGGAGTTTCCTACCGGG-3	NULL
'	NULL
,	NULL
was	NULL
annealed	NULL
with	NULL
a	NULL
complimentary	NULL
primer	NULL
and	NULL
was	NULL
radiolabeled	NULL
using	NULL
[	NULL
aP	NULL
]	NULL
deoxycytidine	NULL
triphosphate	NULL
(	NULL
ICN	NULL
)	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Similarly	NULL
,	NULL
binding	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
,	NULL
EGR-1	NULL
,	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
radiolabeled	NULL
oligonucleotide	NULL
(	NULL
Operon	NULL
Tech	NULL
)	NULL
containing	NULL
a	NULL
prototypic	NULL
EGR-1	NULL
site	NULL
(	NULL
underlined	NULL
)	NULL
,	NULL
_	NULL
Protein-DNA	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
free	NULL
DNA	NULL
probe	NULL
by	NULL
electrophoresis	NULL
through	NULL
6	NULL
%	NULL
nondenaturing	NULL
acrylamide	NULL
gels	NULL
(	NULL
Novex	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
in	NULL
0.5	NULL
%	NULL
Tris	NULL
borate-EDTA	NULL
.	NULL

Band	NULL
intensites	NULL
were	NULL
quantified	NULL
by	NULL
densitometric	NULL
analysis	NULL
using	NULL
a	NULL
Personal	NULL
Densitometer	NULL
and	NULL
ImageQuant	NULL
software	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

Western	NULL
blotting	NULL
.	NULL

-	NULL
Analysis	NULL
of	NULL
IxBa	NULL
protein	NULL
was	NULL
performed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
unstimulated	NULL
or	NULL
were	NULL
LPS-stimulated	NULL
(	NULL
for	NULL
1	NULL
hour	NULL
)	NULL
with	NULL
or	NULL
without	NULL
a	NULL
15-minute	NULL
pretreatment	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
NaSal	NULL
.	NULL

Cytosolic	NULL
extracts	NULL
were	NULL
electropho-resed	NULL
on	NULL
8	NULL
%	NULL
to	NULL
16	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gels	NULL
(	NULL
Novex	NULL
)	NULL
and	NULL
were	NULL
transferred	NULL
to	NULL
Hybond-enhanced	NULL
chemilumines-cence	NULL
(	NULL
ECL	NULL
;	NULL
Amersham	NULL
Corp	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

IxBa	NULL
protein	NULL
was	NULL
detected	NULL
according	NULL
to	NULL
the	NULL
ECL	NULL
protocol	NULL
(	NULL
Amersham	NULL
Corp	NULL
)	NULL
using	NULL
a	NULL
1:2500	NULL
dilution	NULL
of	NULL
an	NULL
IxBa	NULL
antiserum	NULL
kindly	NULL
provided	NULL
by	NULL
W.C.	NULL
Greene	NULL
(	NULL
J.	NULL
David	NULL
Gladstone	NULL
Institute	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

RESULTS	NULL
Salicylates	NULL
inhibit	NULL
LPS-induced	NULL
TF	NULL
expression	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
.	NULL

-	NULL
NaSal	NULL
and	NULL
aspirin	NULL
are	NULL
able	NULL
to	NULL
inhibit	NULL
NF-xB	NULL
activation	NULL
,	NULL
as	NULL
was	NULL
recently	NULL
observed	NULL
.	NULL
``	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
LPS	NULL
induction	NULL
of	NULL
the	NULL
TF	NULL
gene	NULL
requires	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
.	NULL
``	NULL

Therefore	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
various	NULL
salicylates	NULL
and	NULL
other	NULL
NSAIDs	NULL
to	NULL
inhibit	NULL
LPS-induced	NULL
TF	NULL
expression	NULL
in	NULL
both	NULL
PBMCs	NULL
and	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
,	NULL
salsalate	NULL
(	NULL
10	NULL
mmol/	NULL
L	NULL
)	NULL
,	NULL
aspirin	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
,	NULL
ibuprofen	NULL
(	NULL
200	NULL
umol/L	NULL
)	NULL
,	NULL
or	NULL
indomethacin	NULL
(	NULL
25	NULL
umoI/L	NULL
)	NULL
before	NULL
LPS	NULL
stimulation	NULL
for	NULL
5	NULL
hours	NULL
.	NULL

NaSal	NULL
,	NULL
salsalate	NULL
,	NULL
and	NULL
aspirin	NULL
all	NULL
inhibited	NULL
LPS	NULL
induction	NULL
of	NULL
120	NULL
-	NULL
LPS	NULL
100	NULL
so	NULL
so	NULL
40	NULL
Inhibition	NULL
of	NULL
LPS-Induced	NULL
TF	NULL
Activity	NULL
(	NULL
%	NULL
)	NULL
20	NULL
«	NULL
120	NULL
-60	NULL
-30	NULL
-15	NULL
0	NULL
+15	NULL
+30	NULL
+60	NULL
+120	NULL
Addition	NULL
of	NULL
NaSal	NULL
(	NULL
min	NULL
)	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
addition	NULL
of	NULL
NaSal	NULL
before	NULL
and	NULL
after	NULL
LPS	NULL
stimulation	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
before	NULL
and	NULL
after	NULL
LPS	NULL
stimulation	NULL
for	NULL
5	NULL
hours	NULL
.	NULL

The	NULL
NaSal	NULL
inhibition	NULL
(	NULL
%	NULL
)	NULL
of	NULL
LPS-induced	NULL
TF	NULL
activity	NULL
is	NULL
shown	NULL
for	NULL
a	NULL
typical	NULL
experiment	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

SALICYLATES	NULL
INHIBIT	NULL
TISSUE	NULL
FACTOR	NULL
EXPRESSION	NULL
4147	NULL
Control	NULL
(	NULL
MCF=14	NULL
)	NULL
LPS	NULL
(	NULL
MCF=80	NULL
)	NULL
150	NULL
35	NULL
3	NULL
Fig	NULL
4	NULL
.	NULL

-	NULL
NaSal	NULL
inhibition	NULL
of	NULL
LPS-induced	NULL
TF	NULL
antigen	NULL
0.1	NULL
mM	NULL
NaSal	NULL
+	NULL
LPS	NULL
(	NULL
MCF=67	NULL
)	NULL
aud	NULL
0	NULL
101	NULL
10	NULL
0	NULL
10	NULL
_	NULL
104	NULL
10°	NULL
-	NULL
40	NULL
!	NULL

10	NULL
10	NULL
%	NULL
104	NULL
10	NULL
mM	NULL
NaSal	NULL
+	NULL
LPS	NULL
(	NULL
MCF=14	NULL
)	NULL
t	NULL
n	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

PBMCs	NULL
were	NULL
incubated	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
for	NULL
5	NULL
hours	NULL
with	NULL
or	NULL
without	NULL
a	NULL
15-minute	NULL
pretreatment	NULL
with	NULL
NaSal	NULL
(	NULL
0.1	NULL
and	NULL
10	NULL
mmol/L	NULL
}	NULL
.	NULL

The	NULL
control	NULL
sample	NULL
is	NULL
PBMCs	NULL
incubated	NULL
F	NULL
for	NULL
5	NULL
hours	NULL
without	NULL
LPS	NULL
or	NULL
NaSal	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
an	NULL
FITC-labeled	NULL
human	NULL
TF-specific	NULL
monoclonal	NULL
antibody	NULL
,	NULL
TF8-5G9	NULL
.	NULL

Expression	NULL
of	NULL
TF	NULL
on	NULL
the	NULL
cell	NULL
sur-	NULL
[	NULL
face	NULL
was	NULL
determined	NULL
by	NULL
fluorescence-activated	NULL
cell	NULL
sorting	NULL
(	NULL
FACS	NULL
)	NULL
using	NULL
live	NULL
gating	NULL
to	NULL
analyze	NULL
the	NULL
Cell	NULL
Number	NULL
--	NULL
-	NULL
>	NULL
oda	NULL
ca	NULL
Apt	NULL
i	NULL
rium	NULL
ii	NULL
.	NULL

a	NULL
monocyte	NULL
population	NULL
.	NULL

Results	NULL
from	NULL
a	NULL
representative	NULL
(	NULL
20°	NULL
experiment	NULL
are	NULL
expressed	NULL
as	NULL
log	NULL
fluorescence	NULL
inten-	NULL
sity	NULL
versus	NULL
cell	NULL
number	NULL
.	NULL

Mean	NULL
channel	NULL
fluorescence	NULL
{	NULL
(	NULL
MCF	NULL
)	NULL
for	NULL
each	NULL
sample	NULL
is	NULL
shown	NULL
.	NULL

TF	NULL
activity	NULL
in	NULL
PBMCs	NULL
and	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
,	NULL
whereas	NULL
ibuprofen	NULL
and	NULL
indomethacin	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicated	NULL
that	NULL
both	NULL
nonacetylated	NULL
and	NULL
acetylated	NULL
salicylates	NULL
inhibited	NULL
LPS-induced	NULL
TF	NULL
expression	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
various	NULL
doses	NULL
of	NULL
NaSal	NULL
on	NULL
LPS-induced	NULL
TF	NULL
activity	NULL
.	NULL

Both	NULL
PBMCs	NULL
and	NULL
THP-1	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
NaSal	NULL
(	NULL
0.1	NULL
to	NULL
10	NULL
mmol/	NULL
L	NULL
)	NULL
before	NULL
LPS	NULL
stimulation	NULL
for	NULL
5	NULL
hours	NULL
to	NULL
maximally	NULL
induce	NULL
TF	NULL
activity	NULL
.	NULL

NaSal	NULL
inhibited	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
activity	NULL
in	NULL
PBMCs	NULL
and	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Figs	NULL
2A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
using	NULL
aspirin	NULL
and	NULL
salsalate	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Time	NULL
course	NULL
experiments	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
at	NULL
different	NULL
times	NULL
(	NULL
2	NULL
,	NULL
5	NULL
,	NULL
8	NULL
,	NULL
and	NULL
24	NULL
hours	NULL
)	NULL
after	NULL
LPS	NULL
stimulation	NULL
.	NULL

These	NULL
results	NULL
showed	NULL
that	NULL
NaSal	NULL
abolished	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
activity	NULL
at	NULL
all	NULL
time	NULL
points	NULL
examined	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
NaSal	NULL
did	NULL
not	NULL
act	NULL
by	NULL
simply	NULL
delaying	NULL
the	NULL
induction	NULL
of	NULL
TF	NULL
expression	NULL
.	NULL

The	NULL
level	NULL
of	NULL
inhibition	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
NaSal	NULL
at	NULL
various	NULL
times	NULL
before	NULL
and	NULL
after	NULL
LPS	NULL
stimulation	NULL
was	NULL
also	NULL
exam-ined	NULL
.	NULL

LPS	NULL
induction	NULL
of	NULL
TF	NULL
activity	NULL
was	NULL
abolished	NULL
by	NULL
preincu-bating	NULL
cells	NULL
with	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
for	NULL
between	NULL
0	NULL
and	NULL
120	NULL
minutes	NULL
before	NULL
LPS	NULL
stimulation	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
longer	NULL
preincubation	NULL
times	NULL
(	NULL
60	NULL
to	NULL
120	NULL
minutes	NULL
)	NULL
with	NULL
lower	NULL
concentrations	NULL
of	NULL
NaSal	NULL
(	NULL
0.5	NULL
to	NULL
1.0	NULL
mmol/L	NULL
)	NULL
did	NULL
not	NULL
increase	NULL
the	NULL
level	NULL
of	NULL
inhibition	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
there	NULL
was	NULL
a	NULL
time-dependent	NULL
loss	NULL
of	NULL
inhibitory	NULL
activity	NULL
when	NULL
NaSal	NULL
was	NULL
added	NULL
after	NULL
LPS	NULL
stimulation	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

The	NULL
inhibitory	NULL
activity	NULL
required	NULL
the	NULL
continual	NULL
presence	NULL
of	NULL
NaSal	NULL
because	NULL
full	NULL
LPS-induced	NULL
TF	NULL
activity	NULL
was	NULL
recovered	NULL
when	NULL
NaSal	NULL
was	NULL
removed	NULL
before	NULL
LPS	NULL
stimulation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
NaSal	NULL
was	NULL
not	NULL
a	NULL
result	NULL
of	NULL
inhibition	NULL
of	NULL
procoagulant	NULL
activity	NULL
in	NULL
the	NULL
one-stage	NULL
clotting	NULL
assay	NULL
,	NULL
because	NULL
this	NULL
inhibitor	NULL
had	NULL
no	NULL
effect	NULL
10	NULL
!	NULL

_	NULL
10	NULL
106	NULL
_	NULL
10	NULL
10	NULL
_	NULL
10	NULL
Fluorescence	NULL
Intensity	NULL
--	NULL
--	NULL
»	NULL
on	NULL
clotting	NULL
times	NULL
when	NULL
added	NULL
to	NULL
cells	NULL
immediately	NULL
before	NULL
harvest	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

LPS	NULL
induction	NULL
of	NULL
cell-surface	NULL
TF	NULL
expression	NULL
in	NULL
PBMCs	NULL
was	NULL
measured	NULL
to	NULL
determine	NULL
if	NULL
NaSal	NULL
inhibited	NULL
increases	NULL
in	NULL
TF	NULL
protein	NULL
expression	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

PBMCs	NULL
were	NULL
pretreated	NULL
with	NULL
NaSal	NULL
(	NULL
0.1	NULL
and	NULL
10	NULL
mmol/L	NULL
)	NULL
for	NULL
15	NULL
minutes	NULL
before	NULL
a	NULL
5-hour	NULL
incubation	NULL
with	NULL
or	NULL
without	NULL
LPS	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
.	NULL

LPS	NULL
induction	NULL
of	NULL
TF	NULL
expression	NULL
was	NULL
again	NULL
inhibited	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
,	NULL
with	NULL
complete	NULL
inhibition	NULL
at	NULL
10	NULL
mmol/L	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

To	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
inhibition	NULL
by	NULL
NaSal	NULL
was	NULL
due	NULL
to	NULL
toxicity	NULL
,	NULL
we	NULL
examined	NULL
protein	NULL
incorporation	NULL
of	NULL
S-methionine	NULL
and	NULL
*S-cysteine	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
LPS	NULL
and	NULL
various	NULL
concentrations	NULL
of	NULL
NaSal	NULL
.	NULL

Incorporation	NULL
of	NULL
these	NULL
radiolabeled	NULL
amino	NULL
acids	NULL
into	NULL
newly	NULL
synthesized	NULL
cellular	NULL
protein	NULL
is	NULL
a	NULL
general	NULL
measure	NULL
of	NULL
protein	NULL
synthesis	NULL
within	NULL
a	NULL
population	NULL
of	NULL
cells	NULL
.	NULL

PBMCs	NULL
and	NULL
THP-1	NULL
cells	NULL
pretreated	NULL
with	NULL
NaSal	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
LPS	NULL
showed	NULL
no	NULL
significant	NULL
decrease	NULL
in	NULL
protein	NULL
synthesis	NULL
at	NULL
any	NULL
concentration	NULL
of	NULL
NaSal	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
measurement	NULL
of	NULL
cell	NULL
viability	NULL
was	NULL
assessed	NULL
by	NULL
MTS	NULL
conversion	NULL
to	NULL
formazan	NULL
via	NULL
dehydrogenase	NULL
enzymes	NULL
found	NULL
in	NULL
metabolically	NULL
active	NULL
cells	NULL
using	NULL
a	NULL
calorimetric	NULL
assay	NULL
.	NULL

No	NULL
reduction	NULL
in	NULL
cell	NULL
viability	NULL
was	NULL
observed	NULL
using	NULL
LPS	NULL
and	NULL
NaSal	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Trypan	NULL
blue	NULL
cell	NULL
counts	NULL
also	NULL
showed	NULL
no	NULL
significant	NULL
reduction	NULL
in	NULL
cell	NULL
viability	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
we	NULL
observed	NULL
no	NULL
significant	NULL
cell	NULL
toxicity	NULL
at	NULL
the	NULL
concentrations	NULL
of	NULL
NaSal	NULL
and	NULL
LPS	NULL
used	NULL
during	NULL
the	NULL
investigation	NULL
.	NULL

NaSal	NULL
inhibits	NULL
LPS-induced	NULL
TF	NULL
mRNA	NULL
expression	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
if	NULL
NaSal	NULL
inhibited	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
mRNA	NULL
.	NULL

Before	NULL
LPS	NULL
stimulation	NULL
for	NULL
2	NULL
hours	NULL
to	NULL
maximally	NULL
induce	NULL
TF	NULL
mRNA	NULL
,	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
NaSal	NULL
at	NULL
doses	NULL
ranging	NULL
from	NULL
0.1	NULL
to	NULL
10	NULL
mmol/L	NULL
.	NULL

LPS	NULL
induction	NULL
of	NULL
TF	NULL
mRNA	NULL
was	NULL
inhibited	NULL
in	NULL
a	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4148	NULL
3	NULL
>	NULL
3000	NULL
2500	NULL
2000	NULL
1500	NULL
1000	NULL
500	NULL
Normalized	NULL
Levels	NULL
of	NULL
TF	NULL
mRNA	NULL
(	NULL
arbitrary	NULL
units	NULL
)	NULL
TF	NULL
mRNA	NULL
-	NULL
>	NULL
»	NULL
“	NULL
i	NULL
‘	NULL
?	NULL

aime	NULL
c3pon	NULL
-	NULL
»	NULL
.	NULL

LPS	NULL
NaSal	NULL
(	NULL
mM	NULL
)	NULL
+o	NULL
ot	NULL
+	NULL
+0	NULL
+	NULL
+	NULL
0	NULL
0	NULL
0.1	NULL
0.5	NULL
1	NULL
5	NULL
10	NULL
EGR-1	NULL
mRNA	NULL
-	NULL
>	NULL
-_	NULL
@	NULL
#	NULL
@	NULL
lip	NULL
GGP	NULL
DH	NULL
-	NULL
>	NULL
-	NULL
«	NULL
hib	NULL
«	NULL
lh	NULL
dllh	NULL
PMA	NULL
-	NULL
+	NULL
+	NULL
NaSal	NULL
(	NULL
mM	NULL
)	NULL
O	NULL
0	NULL
10	NULL
Fig	NULL
5	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
TF	NULL
mRNA	NULL
expression	NULL
in	NULL
THP-1	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Total	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
THP-1	NULL
cells	NULL
exposed	NULL
to	NULL
LPS	NULL
(	NULL
10	NULL
g/mL	NULL
)	NULL
for	NULL
2	NULL
hours	NULL
with	NULL
or	NULL
without	NULL
a	NULL
15-minute	NULL
pretreatment	NULL
with	NULL
NaSal	NULL
at	NULL
doses	NULL
ranging	NULL
from	NULL
0.1	NULL
to	NULL
10	NULL
mmol/L	NULL
.	NULL

The	NULL
control	NULL
sample	NULL
was	NULL
incubated	NULL
without	NULL
LPS	NULL
or	NULL
NaSal	NULL
.	NULL

TF	NULL
mRNA	NULL
levels	NULL
were	NULL
determined	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
using	NULL
a	NULL
radiolabeled	NULL
human	NULL
TF	NULL
cDNA	NULL
probe	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
reprobed	NULL
to	NULL
determine	NULL
G3PDH	NULL
mRNA	NULL
levels	NULL
as	NULL
a	NULL
measure	NULL
of	NULL
RNA	NULL
loading	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
TF	NULL
mRNA	NULL
is	NULL
indicated	NULL
.	NULL

Band	NULL
intensities	NULL
were	NULL
quantified	NULL
by	NULL
densitometric	NULL
analysis	NULL
using	NULL
a	NULL
Personal	NULL
Densitometer	NULL
and	NULL
ImageQuant	NULL
software	NULL
.	NULL

Normalized	NULL
levels	NULL
of	NULL
TF	NULL
mRNA	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
B	NULL
)	NULL
THP-1	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
PMA	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
for	NULL
2	NULL
hours	NULL
with	NULL
or	NULL
without	NULL
a	NULL
15-minute	NULL
pretreatment	NULL
with	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
.	NULL

Control	NULL
cells	NULL
were	NULL
incubated	NULL
without	NULL
PMA	NULL
or	NULL
NaSal	NULL
.	NULL

EGR-1	NULL
mRNA	NULL
levels	NULL
were	NULL
determined	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
using	NULL
a	NULL
radiolabeled	NULL
human	NULL
egr-1	NULL
cDNA	NULL
probe	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
reprobed	NULL
to	NULL
determine	NULL
glucose	NULL
6-phosphate	NULL
dehydrogenase	NULL
mRNA	NULL
levels	NULL
as	NULL
a	NULL
measure	NULL
of	NULL
loading	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
EGR-1	NULL
mRNA	NULL
is	NULL
indicated	NULL
.	NULL

No	NULL
significant	NULL
differences	NULL
were	NULL
observed	NULL
between	NULL
EGR-1	NULL
mRNA	NULL
levels	NULL
in	NULL
RNA	NULL
prepared	NULL
from	NULL
PMA-treated	NULL
cells	NULL
or	NULL
NaSal-	NULL
and	NULL
PMA-treated	NULL
cells	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
an	NULL
independent	NULL
experiment	NULL
.	NULL

OETH	NULL
AND	NULL
MACKMAN	NULL
pSP73	NULL
-	NULL
_	NULL
>	NULL
i	NULL
f	NULL
t	NULL
G3PDH	NULL
pGEMms3Z	NULL
ir	NULL
-	NULL
M	NULL
TNFo	NULL
-|	NULL
pSP73	NULL
s	NULL
me	NULL
G3PDH	NULL
521	NULL
367	NULL
597	NULL
pGEMsZ	NULL
-	NULL
-	NULL
«	NULL
-TF	NULL
-	NULL
318	NULL
l	NULL
TNFo	NULL
.	NULL

441	NULL
2134	NULL
Control	NULL
-	NULL
+LPS	NULL
_	NULL
+NaSal	NULL
+LPS	NULL
Fig	NULL
6	NULL
.	NULL

Nuclear	NULL
run-on	NULL
analysis	NULL
of	NULL
TF	NULL
gene	NULL
transcription	NULL
in	NULL
THP-1	NULL
cells	NULL
.	NULL

Nuclei	NULL
were	NULL
isolated	NULL
from	NULL
unstimulated	NULL
cells	NULL
{	NULL
control	NULL
}	NULL
,	NULL
cells	NULL
stimulated	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
pg/mL	NULL
)	NULL
for	NULL
1	NULL
hour	NULL
,	NULL
and	NULL
cells	NULL
pretreated	NULL
with	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
for	NULL
15	NULL
minutes	NULL
before	NULL
LPS	NULL
stimulation	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

Labeled	NULL
nuclear	NULL
RNA	NULL
levels	NULL
were	NULL
determined	NULL
by	NULL
hybridization	NULL
to	NULL
various	NULL
target	NULL
cDNAs	NULL
(	NULL
G3PDH	NULL
,	NULL
TF	NULL
,	NULL
and	NULL
TNFa	NULL
)	NULL
and	NULL
vector	NULL
controls	NULL
pSP73	NULL
,	NULL
pGEM3Z	NULL
,	NULL
pSP64	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
autoradiogram	NULL
was	NULL
exposed	NULL
for	NULL
14	NULL
days	NULL
at	NULL
-80°C	NULL
with	NULL
intensifier	NULL
screens	NULL
.	NULL

The	NULL
numbers	NULL
shown	NULL
below	NULL
represent	NULL
band	NULL
intensities	NULL
quantified	NULL
using	NULL
a	NULL
Personal	NULL
Densitometer	NULL
and	NULL
ImageQuant	NULL
software	NULL
.	NULL

No	NULL
hybridization	NULL
was	NULL
detected	NULL
with	NULL
the	NULL
other	NULL
slots	NULL
(	NULL
-	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

dose-dependent	NULL
manner	NULL
by	NULL
NaSal	NULL
(	NULL
Fig	NULL
5A	NULL
)	NULL
.	NULL

To	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
NaSal	NULL
was	NULL
a	NULL
general	NULL
trancriptional	NULL
inhibitor	NULL
of	NULL
THP-1	NULL
cells	NULL
,	NULL
we	NULL
analyzed	NULL
PMA	NULL
induction	NULL
of	NULL
another	NULL
gene	NULL
,	NULL
egr-1	NULL
,	NULL
which	NULL
is	NULL
regulated	NULL
by	NULL
a	NULL
«	NULL
B-independent	NULL
mechanism	NULL
.	NULL

The	NULL
egr-1	NULL
gene	NULL
expresses	NULL
a	NULL
nuclear	NULL
phosphoprotein	NULL
that	NULL
binds	NULL
to	NULL
DNA	NULL
in	NULL
a	NULL
zinc-dependent	NULL
manner	NULL
.	NULL
``	NULL

''	NULL
PMA	NULL
induction	NULL
of	NULL
EGR-1	NULL
mRNA	NULL
expression	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
;	NULL
see	NULL
Fig	NULL
5B	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
NaSal	NULL
was	NULL
not	NULL
acting	NULL
as	NULL
a	NULL
general	NULL
inhibitor	NULL
of	NULL
transcriptional	NULL
activation	NULL
in	NULL
these	NULL
monocytic	NULL
cells	NULL
.	NULL

NaSal	NULL
inhibits	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
gene	NULL
transcription	NULL
and	NULL
the	NULL
human	NULL
TF	NULL
promoter	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
NaSal	NULL
blocked	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
gene	NULL
transcription	NULL
,	NULL
nuclear	NULL
run-on	NULL
experiments	NULL
were	NULL
performed	NULL
.	NULL

LPS	NULL
stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
transiently	NULL
increased	NULL
the	NULL
rate	NULL
of	NULL
TF	NULL
gene	NULL
transcription	NULL
at	NULL
1	NULL
hour	NULL
(	NULL
Fig	NULL
6	NULL
)	NULL
.	NULL

This	NULL
increase	NULL
was	NULL
abolished	NULL
by	NULL
pretreating	NULL
the	NULL
cells	NULL
with	NULL
NaSal	NULL
(	NULL
Fig	NULL
6	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
NaSal	NULL
abolished	NULL
the	NULL
LPS-stimulated	NULL
increase	NULL
in	NULL
TNF-a	NULL
gene	NULL
transcription	NULL
(	NULL
Fig	NULL
6	NULL
)	NULL
,	NULL
which	NULL
is	NULL
also	NULL
regulated	NULL
by	NULL
proteins	NULL
.	NULL
``	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
rate	NULL
of	NULL
transcription	NULL
of	NULL
the	NULL
housekeeping	NULL
gene	NULL
,	NULL
G3PDH	NULL
,	NULL
was	NULL
not	NULL
altered	NULL
by	NULL
LPS	NULL
stimulation	NULL
or	NULL
NaSal	NULL
and	NULL
LPS	NULL
(	NULL
Fig	NULL
6	NULL
)	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

SALICYLATES	NULL
INHIBIT	NULL
TISSUE	NULL
FACTOR	NULL
EXPRESSION	NULL
To	NULL
further	NULL
analyze	NULL
the	NULL
NaSal	NULL
inhibition	NULL
of	NULL
TF	NULL
gene	NULL
transcription	NULL
,	NULL
THP-1	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
plasmid	NULL
,	NULL
pTF	NULL
(	NULL
-278	NULL
)	NULL
LUC	NULL
,	NULL
which	NULL
contains	NULL
278	NULL
bp	NULL
of	NULL
the	NULL
human	NULL
TF	NULL
promoter	NULL
cloned	NULL
upstream	NULL
of	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
,	NULL
and	NULL
a	NULL
plasmid	NULL
,	NULL
p	NULL
(	NULL
TF	NULL
)	NULL
,	NULL
SVLUC	NULL
,	NULL
which	NULL
contains	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
TF	NULL
«	NULL
B	NULL
site	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
minimal	NULL
simian	NULL
virus	NULL
40	NULL
promoter	NULL
expressing	NULL
the	NULL
luciferase	NULL
gene	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
LPS	NULL
induction	NULL
of	NULL
the	NULL
TF	NULL
promoter	NULL
is	NULL
mediated	NULL
by	NULL
an	NULL
LPS	NULL
response	NULL
element	NULL
(	NULL
-227	NULL
to	NULL
172	NULL
bp	NULL
)	NULL
in	NULL
the	NULL
wild-type	NULL
TF	NULL
promoter	NULL
or	NULL
by	NULL
tandem	NULL
copies	NULL
of	NULL
the	NULL
isolated	NULL
TF	NULL
«	NULL
B	NULL
site	NULL
.	NULL
``	NULL

''	NULL
``	NULL
'	NULL
Before	NULL
a	NULL
S-hour	NULL
LPS	NULL
stimulation	NULL
to	NULL
maximally	NULL
induce	NULL
luciferase	NULL
expression	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
NaSal	NULL
in	NULL
doses	NULL
ranging	NULL
from	NULL
0.1	NULL
to	NULL
10	NULL
mmol/L	NULL
.	NULL

LPS	NULL
induction	NULL
of	NULL
luciferase	NULL
activity	NULL
expressed	NULL
by	NULL
pTF	NULL
(	NULL
-278	NULL
)	NULL
LUC	NULL
and	NULL
p	NULL
(	NULL
TF	NULL
)	NULL
,	NULL
SVLUC	NULL
was	NULL
inhibited	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
by	NULL
NaSal	NULL
(	NULL
Fig	NULL
7	NULL
)	NULL
.	NULL

Salicylates	NULL
inhibit	NULL
LPS	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

-	NULL
To	NULL
examine	NULL
if	NULL
NaSal	NULL
acted	NULL
by	NULL
preventing	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
,	NULL
THP-1	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
pTF	NULL
(	NULL
-278	NULL
)	NULL
LUC	NULL
o	NULL
-	NULL
N	NULL
@	NULL
A	NULL
O1	NULL
__	NULL
_w~_	NULL
_c	NULL
p	NULL
(	NULL
TF	NULL
)	NULL
,	NULL
SVLUC	NULL
100	NULL
80	NULL
60	NULL
Fold	NULL
Induction	NULL
of	NULL
Luciferase	NULL
Activity	NULL
40	NULL
20	NULL
0	NULL
LPS	NULL
_-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
NaSal	NULL
-	NULL
-	NULL
0.4	NULL
0.50	NULL
1	NULL
50	NULL
10	NULL
(	NULL
mM	NULL
)	NULL
Fig	NULL
7	NULL
.	NULL

NaSal	NULL
inhibition	NULL
of	NULL
LPS-induced	NULL
TF	NULL
promoter	NULL
activity	NULL
in	NULL
THP-1	NULL
cells	NULL
.	NULL

pTF	NULL
(	NULL
-278	NULL
)	NULL
LUC	NULL
and	NULL
p	NULL
(	NULL
TF	NULL
)	NULL
,	NULL
SVLUC	NULL
were	NULL
transfected	NULL
into	NULL
THP-1	NULL
cells	NULL
.	NULL

After	NULL
46	NULL
hours	NULL
,	NULL
cells	NULL
were	NULL
divided	NULL
into	NULL
equal	NULL
portions	NULL
and	NULL
were	NULL
treated	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
mg/mL	NULL
)	NULL
for	NULL
5	NULL
hours	NULL
with	NULL
or	NULL
without	NULL
a	NULL
15-minute	NULL
pretreatment	NULL
of	NULL
NaSal	NULL
at	NULL
doses	NULL
ranging	NULL
from	NULL
0.1	NULL
to	NULL
10	NULL
mmol/L	NULL
.	NULL

The	NULL
control	NULL
sample	NULL
was	NULL
incubated	NULL
without	NULL
LPS	NULL
or	NULL
NaSal	NULL
.	NULL

Luciferase	NULL
activity	NULL
(	NULL
light	NULL
units	NULL
)	NULL
expressed	NULL
by	NULL
pTF	NULL
(	NULL
-278	NULL
)	NULL
LUC	NULL
and	NULL
p	NULL
(	NULL
TF	NULL
)	NULL
,	NULL
SVLUC	NULL
measured	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
was	NULL
used	NULL
to	NULL
determine	NULL
fold	NULL
inductions	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
)	NULL
.	NULL

4149	NULL
A	NULL
c-Rel/p65~	NULL
>	NULL
-	NULL
Wis	NULL
ma	NULL
I	NULL
@	NULL
A	NULL
0	NULL
@	NULL
@	NULL
Intensity	NULL
of	NULL
Complex	NULL
(	NULL
x10	NULL
)	NULL
o	NULL
“	NULL
CEO	NULL
.	NULL
``	NULL

«	NULL
aam	NULL
<	NULL
i	NULL
>	NULL
.	NULL

ois	NULL
...	NULL
sues	NULL
«	NULL
amie	NULL
aanie	NULL
«	NULL
itt	NULL
LPS	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
NaSal	NULL
(	NULL
mM	NULL
)	NULL
-	NULL
-	NULL
0.105	NULL
1	NULL
5	NULL
10	NULL
C	NULL
PMA	NULL
-	NULL
+	NULL
+	NULL
NaSal	NULL
(	NULL
mM	NULL
)	NULL
O	NULL
0	NULL
10	NULL
Fig	NULL
8	NULL
.	NULL

LPS	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
in	NULL
THP-1	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Nuclear	NULL
extracts	NULL
were	NULL
isolated	NULL
from	NULL
THP-1	NULL
cells	NULL
pretreated	NULL
with	NULL
various	NULL
doses	NULL
of	NULL
NaSal	NULL
(	NULL
0.1	NULL
to	NULL
10	NULL
mmol/L	NULL
)	NULL
for	NULL
15	NULL
minutes	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
LPS	NULL
(	NULL
10	NULL
g/mL	NULL
)	NULL
for	NULL
2	NULL
hours	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
c-Rel/p65	NULL
complex	NULL
in	NULL
the	NULL
EMSA	NULL
is	NULL
indicated	NULL
.	NULL

Band	NULL
intensities	NULL
were	NULL
quantified	NULL
by	NULL
densitometric	NULL
analysis	NULL
using	NULL
a	NULL
Personal	NULL
Densitometer	NULL
and	NULL
ImageQuant	NULL
software	NULL
.	NULL

(	NULL
B	NULL
)	NULL
IxBa	NULL
protein	NULL
levels	NULL
were	NULL
determined	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

Cytosolic	NULL
samples	NULL
were	NULL
prepared	NULL
from	NULL
THP-1	NULL
cells	NULL
pretreated	NULL
with	NULL
NaSal	NULL
for	NULL
15	NULL
minutes	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
LPS	NULL
for	NULL
1	NULL
hour	NULL
.	NULL

IxBa	NULL
protein	NULL
was	NULL
detected	NULL
using	NULL
the	NULL
ECL	NULL
protocol	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Nuclear	NULL
extracts	NULL
were	NULL
isolated	NULL
from	NULL
THP-1	NULL
cells	NULL
pretreated	NULL
with	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
before	NULL
addition	NULL
of	NULL
PMA	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
for	NULL
2	NULL
hours	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
EGR-1	NULL
complex	NULL
is	NULL
indicated	NULL
.	NULL

Control	NULL
samples	NULL
were	NULL
incubated	NULL
without	NULL
LPS	NULL
or	NULL
PMA	NULL
or	NULL
NaSal	NULL
.	NULL

EGR-1	NULL
15	NULL
minutes	NULL
with	NULL
NaSal	NULL
(	NULL
0.1	NULL
to	NULL
10	NULL
mmol/L	NULL
)	NULL
before	NULL
a	NULL
2-hour	NULL
LPS	NULL
stimulation	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
using	NULL
a	NULL
radiolabeled	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
TF	NULL
«	NULL
kB	NULL
site	NULL
.	NULL
``	NULL

''	NULL
LPS	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
in	NULL
THP-I1	NULL
cells	NULL
was	NULL
inhibited	NULL
by	NULL
NaSal	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Fig	NULL
8A	NULL
)	NULL
.	NULL

NaSal	NULL
also	NULL
inhibited	NULL
the	NULL
LPS	NULL
activation	NULL
of	NULL
NF-kB	NULL
(	NULL
p50/p65	NULL
)	NULL
in	NULL
THP-1	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Western	NULL
blots	NULL
showed	NULL
that	NULL
NaSal	NULL
prevented	NULL
the	NULL
reduction	NULL
in	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4150	NULL
IkBa	NULL
protein	NULL
in	NULL
the	NULL
cytosol	NULL
1	NULL
hour	NULL
after	NULL
LPS	NULL
stimulation	NULL
(	NULL
Fig	NULL
8B	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
LPS	NULL
for	NULL
2	NULL
hours	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicated	NULL
that	NULL
NaSal	NULL
inhibited	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
by	NULL
preventing	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IxBa	NULL
protein	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

To	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
NaSal	NULL
nonspecifically	NULL
inhibited	NULL
protein-DNA	NULL
interactions	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
binding	NULL
of	NULL
EGR-1	NULL
to	NULL
a	NULL
prototypic	NULL
EGR-1	NULL
site	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
THP-1	NULL
cells	NULL
with	NULL
or	NULL
without	NULL
NaSal	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
before	NULL
a	NULL
2-hour	NULL
PMA	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
stimulation	NULL
.	NULL

EMSA	NULL
showed	NULL
that	NULL
EGR-1	NULL
binding	NULL
activity	NULL
induced	NULL
by	NULL
PMA	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
NaSal	NULL
(	NULL
Fig	NULL
8C	NULL
)	NULL
.	NULL

Other	NULL
NSAIDs	NULL
,	NULL
including	NULL
salsalate	NULL
,	NULL
aspirin	NULL
,	NULL
ibuprofen	NULL
,	NULL
and	NULL
indomethacin	NULL
,	NULL
were	NULL
examined	NULL
to	NULL
determine	NULL
if	NULL
these	NULL
agents	NULL
also	NULL
inhibited	NULL
the	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
aspirin	NULL
(	NULL
10	NULL
mmol/	NULL
L	NULL
)	NULL
,	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
,	NULL
salsalate	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
,	NULL
ibuprofen	NULL
(	NULL
200	NULL
mol/L	NULL
)	NULL
,	NULL
or	NULL
indomethacin	NULL
(	NULL
25	NULL
pmol/L	NULL
)	NULL
and	NULL
then	NULL
were	NULL
stimulated	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
g/mL	NULL
)	NULL
for	NULL
2	NULL
hours	NULL
.	NULL

Aspirin	NULL
,	NULL
NaSal	NULL
,	NULL
and	NULL
salsalate	NULL
all	NULL
abolished	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
c-Rel/	NULL
p65	NULL
heterodimers	NULL
,	NULL
whereas	NULL
ibuprofen	NULL
and	NULL
indomethacin	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
9	NULL
)	NULL
,	NULL
which	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
inability	NULL
of	NULL
ibuprofen	NULL
and	NULL
indomethacin	NULL
to	NULL
inhibit	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
activity	NULL
in	NULL
monocytic	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

NaSal	NULL
concentrations	NULL
inhibiting	NULL
50	NULL
%	NULL
of	NULL
the	NULL
LPS-induced	NULL
TF	NULL
expression	NULL
in	NULL
the	NULL
different	NULL
assays	NULL
(	NULL
IC	NULL
,	NULL
,	NULL
)	NULL
were	NULL
0.656	NULL
to	NULL
1.030	NULL
mmol/L	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Differences	NULL
in	NULL
the	NULL
ICs	NULL
,	NULL
may	NULL
be	NULL
caused	NULL
by	NULL
the	NULL
different	NULL
incubation	NULL
times	NULL
of	NULL
these	NULL
assays	NULL
or	NULL
may	NULL
reflect	NULL
variations	NULL
in	NULL
the	NULL
sensitivity	NULL
of	NULL
each	NULL
assay	NULL
to	NULL
inhibition	NULL
by	NULL
NaSal	NULL
.	NULL

DISCUSSION	NULL
This	NULL
study	NULL
showed	NULL
that	NULL
salicylates	NULL
inhibited	NULL
LPS-induced	NULL
TF	NULL
expression	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
.	NULL

This	NULL
inhibition	NULL
was	NULL
observed	NULL
with	NULL
NaSal	NULL
,	NULL
salsalate	NULL
,	NULL
and	NULL
aspirin	NULL
,	NULL
indicating	NULL
that	NULL
both	NULL
nonacetylated	NULL
and	NULL
acetylated	NULL
salicylates	NULL
share	NULL
a	NULL
common	NULL
pathway	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
inhibit	NULL
TF	NULL
expression	NULL
.	NULL

NaSal	NULL
inhibited	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
activity	NULL
,	NULL
TF	NULL
mRNA	NULL
,	NULL
and	NULL
TF	NULL
gene	NULL
transcription	NULL
but	NULL
did	NULL
not	NULL
prevent	NULL
PMA	NULL
induction	NULL
of	NULL
EGR-1	NULL
mRNA	NULL
expression	NULL
,	NULL
indicating	NULL
that	NULL
it	NULL
was	NULL
not	NULL
a	NULL
general	NULL
inhibitor	NULL
of	NULL
transcriptional	NULL
activation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
NaSal	NULL
inhibited	NULL
LPS-induced	NULL
nuclear	NULL
translocation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

Other	NULL
NSAIDs	NULL
,	NULL
such	NULL
as	NULL
ibuprofen	NULL
or	NULL
indomethacin	NULL
,	NULL
failed	NULL
to	NULL
inhibit	NULL
LPS-induced	NULL
TF	NULL
activity	NULL
or	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

Thus	NULL
,	NULL
salicylates	NULL
suppressed	NULL
LPS	NULL
induction	NULL
of	NULL
the	NULL
TF	NULL
gene	NULL
in	NULL
monocytic	NULL
cells	NULL
by	NULL
preventing	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

LPS	NULL
stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
lead	NULL
to	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
,	NULL
with	NULL
a	NULL
corresponding	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
containing	NULL
c-Rel	NULL
and	NULL
p65	NULL
.	NULL

*	NULL
'	NULL
We	NULL
have	NULL
shown	NULL
that	NULL
LPS	NULL
stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
transiently	NULL
reduces	NULL
levels	NULL
of	NULL
cytosolic	NULL
IxBa	NULL
protein®	NULL
and	NULL
that	NULL
overex-pression	NULL
of	NULL
IxBa	NULL
in	NULL
THP-1	NULL
cells	NULL
prevents	NULL
LPS	NULL
induction	NULL
of	NULL
TF	NULL
gene	NULL
transcription	NULL
.	NULL
``	NULL

Here	NULL
,	NULL
we	NULL
show	NULL
that	NULL
NaSal	NULL
blocks	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
in	NULL
monocytic	NULL
cells	NULL
by	NULL
preventing	NULL
the	NULL
LPS-induced	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IkBa	NULL
.	NULL

TF	NULL
is	NULL
expressed	NULL
by	NULL
monocytes/macrophages	NULL
in	NULL
rheumatoid	NULL
OETH	NULL
AND	NULL
MACKMAN	NULL
5	NULL
e	NULL
®	NULL
5	NULL
€	NULL
C	NULL
o	NULL
4	NULL
o	NULL
‘	NULL
:	NULL
—_°E	NULL
=	NULL
G	NULL
O	NULL
&	NULL
a	NULL
#	NULL
9	NULL
8	NULL
3	NULL
nsaip	NULL
-	NULL
-	NULL
2	NULL
$	NULL
§	NULL
a	NULL
E	NULL
LPS	NULL
-	NULL
o	NULL
+o+o	NULL
4+	NULL
4+	NULL
4+	NULL
+	NULL
c-Rel/p65	NULL
-	NULL
»	NULL
l	NULL
z	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
Fig	NULL
9	NULL
.	NULL

LPS	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
NSAIDs	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
isolated	NULL
from	NULL
THP-1	NULL
cells	NULL
pretreated	NULL
with	NULL
aspirin	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
,	NULL
NaSal	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
,	NULL
salsalate	NULL
(	NULL
10	NULL
mmol/L	NULL
)	NULL
,	NULL
ibuprofen	NULL
(	NULL
200	NULL
mmol/L	NULL
}	NULL
,	NULL
or	NULL
indomethacin	NULL
(	NULL
25	NULL
pmol/L	NULL
)	NULL
for	NULL
15	NULL
minutes	NULL
before	NULL
stimulation	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
mg/mL	NULL
)	NULL
for	NULL
2	NULL
hours	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
c-Rel/p65	NULL
complex	NULL
in	NULL
the	NULL
EMSA	NULL
is	NULL
indicated	NULL
.	NULL

arthritis	NULL
in	NULL
which	NULL
increased	NULL
levels	NULL
of	NULL
TF	NULL
are	NULL
found	NULL
in	NULL
the	NULL
synovium	NULL
of	NULL
patients	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
TF	NULL
protein	NULL
and	NULL
mRNA	NULL
are	NULL
expressed	NULL
by	NULL
macrophage-derived	NULL
foam	NULL
cells	NULL
in	NULL
atherosclerotic	NULL
plaques	NULL
.	NULL
``	NULL

Both	NULL
of	NULL
these	NULL
diseases	NULL
are	NULL
treated	NULL
clinically	NULL
with	NULL
salicylates	NULL
;	NULL
therefore	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
salicylates	NULL
to	NULL
inhibit	NULL
TF	NULL
expression	NULL
by	NULL
monocytes	NULL
may	NULL
contribute	NULL
to	NULL
their	NULL
efficacy	NULL
and	NULL
antithrombotic	NULL
properties	NULL
.	NULL

Cell	NULL
surface	NULL
expression	NULL
of	NULL
TF	NULL
by	NULL
monocyte/macrophages	NULL
and	NULL
secretion	NULL
of	NULL
various	NULL
cytokines	NULL
,	NULL
including	NULL
TNFa	NULL
,	NULL
are	NULL
associated	NULL
with	NULL
the	NULL
pathology	NULL
of	NULL
Gram-negative	NULL
sepsis	NULL
.	NULL
``	NULL

An	NULL
effective	NULL
clinical	NULL
inhibitor	NULL
of	NULL
transcriptional	NULL
activation	NULL
of	NULL
TF	NULL
and	NULL
cytokine	NULL
genes	NULL
could	NULL
be	NULL
useful	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
sepsis	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
found	NULL
that	NULL
NaSal	NULL
inhibited	NULL
LPS-induced	NULL
transcription	NULL
of	NULL
both	NULL
the	NULL
TF	NULL
and	NULL
TNFa	NULL
genes	NULL
in	NULL
THP-1	NULL
monocytic	NULL
cells	NULL
.	NULL

Aspirin	NULL
has	NULL
previously	NULL
been	NULL
examined	NULL
in	NULL
rat	NULL
and	NULL
nonhuman	NULL
primate	NULL
models	NULL
of	NULL
endotoxemia	NULL
with	NULL
beneficial	NULL
results	NULL
``	NULL
``	NULL
;	NULL
however	NULL
,	NULL
no	NULL
follow-up	NULL
studies	NULL
assessed	NULL
its	NULL
clinical	NULL
use	NULL
in	NULL
sepsis	NULL
therapy	NULL
.	NULL

Another	NULL
NSAID	NULL
,	NULL
ibuprofen	NULL
,	NULL
has	NULL
been	NULL
extensively	NULL
studied	NULL
in	NULL
relation	NULL
to	NULL
sepsis	NULL
therapy	NULL
.	NULL
``	NULL

Ibuprofen	NULL
clearly	NULL
reduces	NULL
certain	NULL
symptoms	NULL
observed	NULL
during	NULL
septic	NULL
shock	NULL
,	NULL
such	NULL
as	NULL
increased	NULL
cardiac	NULL
output	NULL
,	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

SALICYLATES	NULL
INHIBIT	NULL
TISSUE	NULL
FACTOR	NULL
EXPRESSION	NULL
4151	NULL
Table	NULL
1	NULL
.	NULL

Inhibition	NULL
(	NULL
%	NULL
}	NULL
of	NULL
c-Rel/p65	NULL
Activation	NULL
and	NULL
TF	NULL
Expression	NULL
by	NULL
Sodium	NULL
Salicylate	NULL
NaSal	NULL
Concentration	NULL
{	NULL
mmol/L	NULL
)	NULL
Assay	NULL
0.1	NULL
0.5	NULL
1	NULL
5	NULL
10	NULL
ICsp	NULL
{	NULL
mmol/L	NULL
)	NULL
Clotting	NULL
,	NULL
PBMC	NULL
(	NULL
5	NULL
h	NULL
)	NULL
PCA	NULL
19	NULL
+	NULL
15	NULL
41	NULL
+	NULL
8	NULL
62	NULL
+	NULL
7	NULL
717	NULL
#	NULL
5	NULL
93	NULL
+	NULL
9	NULL
0.656	NULL
Clotting	NULL
,	NULL
THP-1	NULL
(	NULL
5	NULL
h	NULL
)	NULL
PCA	NULL
17	NULL
+	NULL
13	NULL
28	NULL
+	NULL
19	NULL
59	NULL
+	NULL
11	NULL
76	NULL
+	NULL
3	NULL
99	NULL
*	NULL
2	NULL
0.711	NULL
Northern	NULL
(	NULL
2	NULL
h	NULL
}	NULL
TF	NULL
mRNA	NULL
18	NULL
+	NULL
2	NULL
32	NULL
+	NULL
3	NULL
47	NULL
x7	NULL
74	NULL
+	NULL
4	NULL
92	NULL
+	NULL
9	NULL
0.920	NULL
Transfection	NULL
(	NULL
5	NULL
h	NULL
)	NULL
TF	NULL
promoter	NULL
26	NULL
+	NULL
24	NULL
40	NULL
+	NULL
21	NULL
44	NULL
+	NULL
20	NULL
57	NULL
+	NULL
24	NULL
93	NULL
*	NULL
7	NULL
1.107	NULL
Transfection	NULL
(	NULL
5	NULL
h	NULL
}	NULL
TF	NULL
«	NULL
B-mediated	NULL
transcription	NULL
17	NULL
*	NULL
16	NULL
27	NULL
*	NULL
16	NULL
61	NULL
+	NULL
4	NULL
72	NULL
+	NULL
7	NULL
85	NULL
+	NULL
5	NULL
1.030	NULL
EMSA	NULL
(	NULL
2	NULL
h	NULL
}	NULL
c-Rel/p65	NULL
activation	NULL
18	NULL
+	NULL
17	NULL
20	NULL
+	NULL
17	NULL
51	NULL
+	NULL
10	NULL
65	NULL
*	NULL
14	NULL
93	NULL
+	NULL
2	NULL
1.110	NULL
The	NULL
dose-dependent	NULL
inhibition	NULL
(	NULL
%	NULL
)	NULL
(	NULL
mean	NULL
+	NULL
SD	NULL
)	NULL
was	NULL
calculated	NULL
from	NULL
at	NULL
least	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

NaSal	NULL
concentrations	NULL
inhibiting	NULL
50	NULL
%	NULL
of	NULL
the	NULL
LPS	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
and	NULL
LPS-induced	NULL
TF	NULL
expression	NULL
(	NULL
ICs	NULL
,	NULL
)	NULL
were	NULL
determined	NULL
from	NULL
linear	NULL
regression	NULL
(	NULL
Microsoft	NULL
Excel	NULL
;	NULL
Microsoft	NULL
Corp	NULL
,	NULL
Bothell	NULL
,	NULL
WA	NULL
)	NULL
.	NULL

elevated	NULL
mean	NULL
arterial	NULL
blood	NULL
pressure	NULL
,	NULL
and	NULL
end	NULL
products	NULL
of	NULL
the	NULL
cyclooxygenase	NULL
pathway	NULL
.	NULL
``	NULL

In	NULL
contrast	NULL
,	NULL
endotoxin-induced	NULL
elevation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-regulated	NULL
genes	NULL
interleukin-6	NULL
and	NULL
TNFa	NULL
were	NULL
not	NULL
decreased	NULL
by	NULL
ibuprofen	NULL
administration	NULL
.	NULL
``	NULL

Indomethacin	NULL
,	NULL
another	NULL
NSAID	NULL
,	NULL
which	NULL
(	NULL
like	NULL
ibuprofen	NULL
)	NULL
inhibits	NULL
cyclooxygenase	NULL
,	NULL
was	NULL
unable	NULL
to	NULL
inhibit	NULL
transcription	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL
``	NULL

Our	NULL
data	NULL
and	NULL
those	NULL
of	NULL
others	NULL
``	NULL
show	NULL
that	NULL
ibuprofen	NULL
and	NULL
indomethacin	NULL
failed	NULL
to	NULL
inhibit	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
,	NULL
which	NULL
is	NULL
consistent	NULL
with	NULL
their	NULL
inability	NULL
to	NULL
reduce	NULL
transcription	NULL
of	NULL
NF-	NULL
«	NULL
B/Rel-regulated	NULL
genes	NULL
.	NULL
``	NULL

Sepsis	NULL
is	NULL
a	NULL
complex	NULL
pathological	NULL
condi-tion	NULL
``	NULL
that	NULL
will	NULL
most	NULL
likely	NULL
require	NULL
a	NULL
well-defined	NULL
multiple-drug	NULL
treatment	NULL
for	NULL
effective	NULL
therapy	NULL
.	NULL

Given	NULL
the	NULL
new	NULL
findings	NULL
in	NULL
relation	NULL
to	NULL
the	NULL
modes	NULL
of	NULL
action	NULL
observed	NULL
with	NULL
salicylates	NULL
,	NULL
it	NULL
seems	NULL
their	NULL
use	NULL
in	NULL
sepsis	NULL
therapy	NULL
should	NULL
be	NULL
reexamined	NULL
.	NULL

NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
regulate	NULL
the	NULL
activation	NULL
of	NULL
many	NULL
genes	NULL
that	NULL
are	NULL
induced	NULL
during	NULL
inflammatory	NULL
responses	NULL
,	NULL
including	NULL
genes	NULL
encoding	NULL
various	NULL
cytokines	NULL
and	NULL
adhesion	NULL
molecules	NULL
.	NULL
``	NULL

LPS	NULL
induction	NULL
of	NULL
these	NULL
genes	NULL
is	NULL
mediated	NULL
by	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
.	NULL
``	NULL

''	NULL
Therefore	NULL
,	NULL
inhibiting	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
,	NULL
especially	NULL
in	NULL
monocytes	NULL
,	NULL
may	NULL
account	NULL
for	NULL
many	NULL
of	NULL
the	NULL
anti-inflammatory	NULL
effects	NULL
of	NULL
the	NULL
salicylates	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
acknowledge	NULL
H.	NULL
Larson	NULL
and	NULL
M.	NULL
Smith	NULL
for	NULL
their	NULL
excellent	NULL
technical	NULL
assistance	NULL
,	NULL
V.	NULL
Ollivier	NULL
(	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
)	NULL
for	NULL
help	NULL
with	NULL
the	NULL
nuclear	NULL
run-on	NULL
experiments	NULL
,	NULL
W.C.	NULL
Greene	NULL
(	NULL
J.	NULL
David	NULL
Gladstone	NULL
Institute	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
supplying	NULL
IxBa	NULL
antise-rum	NULL
,	NULL
D.	NULL
Nielsen	NULL
and	NULL
B.	NULL
Parker	NULL
for	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
,	NULL
and	NULL
G.	NULL
Parry	NULL
and	NULL
L.	NULL
Curtiss	NULL
(	NULL
The	NULL
Scripps	NULL
Research	NULL
Institute	NULL
)	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Bach	NULL
RR	NULL
:	NULL
Initiation	NULL
of	NULL
coagulation	NULL
by	NULL
tissue	NULL
factor	NULL
.	NULL

Crit	NULL
Rev	NULL
Biochem	NULL
23:339	NULL
,	NULL
1988	NULL
2	NULL
.	NULL

Edgington	NULL
TS	NULL
,	NULL
Mackman	NULL
N	NULL
,	NULL
Brand	NULL
K	NULL
,	NULL
Ruf	NULL
W	NULL
;	NULL
The	NULL
structural	NULL
biology	NULL
of	NULL
expression	NULL
and	NULL
function	NULL
of	NULL
tissue	NULL
factor	NULL
.	NULL

Thromb	NULL
Haemost	NULL
66:67	NULL
,	NULL
1991	NULL
3	NULL
.	NULL

Wilcox	NULL
JN	NULL
,	NULL
Smith	NULL
KM	NULL
,	NULL
Schwartz	NULL
SM	NULL
,	NULL
Gordon	NULL
D	NULL
:	NULL
Localization	NULL
of	NULL
tissue	NULL
factor	NULL
in	NULL
the	NULL
normal	NULL
vessel	NULL
wall	NULL
and	NULL
in	NULL
the	NULL
atherosclerotic	NULL
plaque	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86:2839	NULL
,	NULL
1989	NULL
4	NULL
.	NULL

Weinberg	NULL
JB	NULL
,	NULL
Pippen	NULL
AMM	NULL
,	NULL
Greenberg	NULL
CS	NULL
:	NULL
Extravascular	NULL
fibrin	NULL
formation	NULL
and	NULL
dissolution	NULL
in	NULL
synovial	NULL
tissue	NULL
of	NULL
patients	NULL
with	NULL
osteoarthritis	NULL
and	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
34:996	NULL
,	NULL
1991	NULL
5	NULL
.	NULL

Osterud	NULL
B	NULL
,	NULL
Flestad	NULL
T	NULL
:	NULL
Increased	NULL
tissue	NULL
thromboplastin	NULL
activity	NULL
in	NULL
monocytes	NULL
of	NULL
patients	NULL
with	NULL
meningococcal	NULL
infection	NULL
:	NULL
Related	NULL
to	NULL
an	NULL
unfavorable	NULL
prognosis	NULL
.	NULL

Thromb	NULL
Haemost	NULL
49:5	NULL
,	NULL
1983	NULL
6	NULL
.	NULL

Dorvak	NULL
HF	NULL
:	NULL
Thrombosis	NULL
and	NULL
cancer	NULL
.	NULL

Hum	NULL
Pathol	NULL
18:275	NULL
,	NULL
1987	NULL
7	NULL
.	NULL

Bauer	NULL
KA	NULL
,	NULL
Conway	NULL
EM	NULL
,	NULL
Bach	NULL
R	NULL
,	NULL
Konigsberg	NULL
WH	NULL
,	NULL
Griffin	NULL
JD	NULL
,	NULL
Demetri	NULL
G	NULL
:	NULL
Tissue	NULL
factor	NULL
gene	NULL
expression	NULL
in	NULL
acute	NULL
myeloblastic	NULL
leukemia	NULL
.	NULL

Thromb	NULL
Res	NULL
56:425	NULL
,	NULL
1989	NULL
8	NULL
.	NULL

Okajima	NULL
K	NULL
,	NULL
Yang	NULL
W-P	NULL
,	NULL
Okabe	NULL
H	NULL
,	NULL
Inoue	NULL
M	NULL
,	NULL
Takatsuki	NULL
K	NULL
:	NULL
Role	NULL
of	NULL
leukocytes	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
intravascular	NULL
coagulation	NULL
in	NULL
patients	NULL
with	NULL
septicemia	NULL
.	NULL

Am	NULL
J	NULL
Hematol	NULL
36:265	NULL
,	NULL
1991	NULL
9	NULL
.	NULL

Rapaport	NULL
SI	NULL
,	NULL
Tatter	NULL
D	NULL
,	NULL
Coeur-Barron	NULL
N	NULL
,	NULL
Hjort	NULL
PF	NULL
:	NULL
Pseudomo-nas	NULL
septicemia	NULL
with	NULL
intravascular	NULL
clotting	NULL
leading	NULL
to	NULL
the	NULL
generalized	NULL
Shwartzman	NULL
reaction	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
271:80	NULL
,	NULL
1964	NULL
10	NULL
.	NULL

Sandset	NULL
PM	NULL
,	NULL
Warn-Cramer	NULL
BJ	NULL
,	NULL
Rao	NULL
LVM	NULL
,	NULL
Maki	NULL
SL	NULL
,	NULL
Rapaport	NULL
SI	NULL
:	NULL
Depletion	NULL
of	NULL
extrinsic	NULL
pathway	NULL
inhibitor	NULL
(	NULL
EPI	NULL
)	NULL
sensitizes	NULL
rabbits	NULL
to	NULL
disseminated	NULL
intravascular	NULL
coagulation	NULL
induced	NULL
with	NULL
tissue	NULL
factor	NULL
:	NULL
Evidence	NULL
supporting	NULL
a	NULL
physiologic	NULL
role	NULL
for	NULL
EPI	NULL
as	NULL
a	NULL
natural	NULL
anticoag-ulant	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
88:708	NULL
,	NULL
1991	NULL
11	NULL
.	NULL

Warr	NULL
TA	NULL
,	NULL
Rao	NULL
LVM	NULL
,	NULL
Rapaport	NULL
SI	NULL
:	NULL
Disseminated	NULL
intravascular	NULL
coagulation	NULL
in	NULL
rabbits	NULL
induced	NULL
by	NULL
administration	NULL
of	NULL
endotoxin	NULL
or	NULL
tissue	NULL
factor	NULL
:	NULL
Effect	NULL
of	NULL
anti-tissue	NULL
factor	NULL
antibodies	NULL
and	NULL
measurement	NULL
of	NULL
plasma	NULL
extrinsic	NULL
pathway	NULL
inhibitor	NULL
activity	NULL
.	NULL

Blood	NULL
75:1481	NULL
,	NULL
1990	NULL
12	NULL
.	NULL

Taylor	NULL
FB	NULL
Jr	NULL
,	NULL
Chang	NULL
A	NULL
,	NULL
Ruf	NULL
W	NULL
,	NULL
Morrissey	NULL
JH	NULL
,	NULL
Hinshaw	NULL
L	NULL
,	NULL
Catlett	NULL
R	NULL
,	NULL
Blick	NULL
K	NULL
,	NULL
Edgington	NULL
TS	NULL
:	NULL
Lethal	NULL
E.	NULL
coli	NULL
septic	NULL
shock	NULL
is	NULL
prevented	NULL
by	NULL
blocking	NULL
tissue	NULL
factor	NULL
with	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Cire	NULL
Shock	NULL
33:127	NULL
,	NULL
1991	NULL
13	NULL
.	NULL

Levy	NULL
GA	NULL
,	NULL
Cole	NULL
EH	NULL
:	NULL
The	NULL
monocyte	NULL
and	NULL
disseminated	NULL
intravascular	NULL
coagulation	NULL
,	NULL
in	NULL
Zembala	NULL
M	NULL
,	NULL
Asherton	NULL
GL	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Human	NULL
Monocytes	NULL
.	NULL

San	NULL
Diego	NULL
,	NULL
CA	NULL
,	NULL
Academic	NULL
,	NULL
1989	NULL
,	NULL
p	NULL
429	NULL
14	NULL
.	NULL

Levi	NULL
M	NULL
,	NULL
ten	NULL
Cate	NULL
H	NULL
,	NULL
Bauer	NULL
KA	NULL
,	NULL
van	NULL
der	NULL
Poll	NULL
T	NULL
,	NULL
Edgington	NULL
TS	NULL
,	NULL
Biiller	NULL
HR	NULL
,	NULL
van	NULL
Deventer	NULL
SJH	NULL
,	NULL
Hack	NULL
CE	NULL
,	NULL
Wouter	NULL
ten	NULL
Cate	NULL
J	NULL
,	NULL
Rosenberg	NULL
RD	NULL
:	NULL
Inhibition	NULL
of	NULL
endotoxin-induced	NULL
activation	NULL
of	NULL
coagulation	NULL
and	NULL
fibrinolysis	NULL
by	NULL
pentoxifylline	NULL
or	NULL
by	NULL
a	NULL
monoclonal	NULL
anti-tissue	NULL
factor	NULL
antibody	NULL
in	NULL
chimpanzees	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
93:114	NULL
,	NULL
1994	NULL
15	NULL
.	NULL

Crutchley	NULL
DJ	NULL
,	NULL
Hirsh	NULL
MJ	NULL
:	NULL
The	NULL
stable	NULL
prostacyclin	NULL
analog	NULL
,	NULL
ilo-prost	NULL
,	NULL
and	NULL
prostaglandin	NULL
E	NULL
,	NULL
inhibit	NULL
monocyte	NULL
procoagulant	NULL
activity	NULL
in	NULL
vitro	NULL
.	NULL

Blood	NULL
78:382	NULL
,	NULL
1991	NULL
16.	NULL
de	NULL
Prost	NULL
D	NULL
,	NULL
Ollivier	NULL
V	NULL
,	NULL
Hakim	NULL
J	NULL
:	NULL
Pentoxifylline	NULL
inhibition	NULL
of	NULL
procoagulant	NULL
activity	NULL
generated	NULL
by	NULL
activated	NULL
mononuclear	NULL
phago-cytes	NULL
.	NULL

Mol	NULL
Pharmacol	NULL
38:562	NULL
,	NULL
1990	NULL
17	NULL
.	NULL

Ollivier	NULL
V	NULL
,	NULL
Ternisien	NULL
C	NULL
,	NULL
Vu	NULL
T	NULL
,	NULL
Hakim	NULL
J	NULL
,	NULL
de	NULL
Prost	NULL
D	NULL
:	NULL
Pentoxi-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

4152	NULL
fylline	NULL
inhibits	NULL
the	NULL
expression	NULL
of	NULL
tissue	NULL
factor	NULL
mRNA	NULL
in	NULL
endotoxin-activated	NULL
human	NULL
monocytes	NULL
.	NULL

FEBS	NULL
Lett	NULL
322:231	NULL
,	NULL
1993	NULL
18	NULL
.	NULL

Gregory	NULL
SA	NULL
,	NULL
Morrissey	NULL
JH	NULL
,	NULL
Edgington	NULL
TS	NULL
:	NULL
Regulation	NULL
of	NULL
tissue	NULL
factor	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
monocyte	NULL
procoagulant	NULL
response	NULL
to	NULL
endotoxin	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
9:2752	NULL
,	NULL
1989	NULL
19	NULL
.	NULL

Brand	NULL
K	NULL
,	NULL
Fowler	NULL
BJ	NULL
,	NULL
Edgington	NULL
TS	NULL
,	NULL
Mackman	NULL
N	NULL
:	NULL
Tissue	NULL
factor	NULL
mRNA	NULL
in	NULL
THP-I	NULL
monocytic	NULL
cells	NULL
is	NULL
regulated	NULL
at	NULL
both	NULL
transcriptional	NULL
and	NULL
posttranscriptional	NULL
levels	NULL
in	NULL
response	NULL
to	NULL
lipopolysac-charide	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
11:4732	NULL
,	NULL
1991	NULL
20	NULL
.	NULL

Mackman	NULL
N	NULL
,	NULL
Brand	NULL
K	NULL
,	NULL
Edgington	NULL
TS	NULL
:	NULL
Lipopolysaccharide-mediated	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
tissue	NULL
factor	NULL
gene	NULL
in	NULL
THP-1	NULL
monocytic	NULL
cells	NULL
requires	NULL
both	NULL
activator	NULL
protein	NULL
1	NULL
and	NULL
nuclear	NULL
factor	NULL
xB	NULL
binding	NULL
sites	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
174:1517	NULL
,	NULL
1991	NULL
21	NULL
.	NULL

Oeth	NULL
PA	NULL
,	NULL
Parry	NULL
GCN	NULL
,	NULL
Kunsch	NULL
C	NULL
,	NULL
Nantermet	NULL
P	NULL
,	NULL
Rosen	NULL
CA	NULL
,	NULL
Mackman	NULL
N	NULL
:	NULL
LPS	NULL
induction	NULL
of	NULL
tissue	NULL
factor	NULL
gene	NULL
expression	NULL
in	NULL
monocytic	NULL
cells	NULL
is	NULL
mediated	NULL
by	NULL
binding	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
to	NULL
a	NULL
«	NULL
B-like	NULL
site	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14:3772	NULL
,	NULL
1994	NULL
22	NULL
.	NULL

Grilli	NULL
M	NULL
,	NULL
Chiu	NULL
JJ-S	NULL
,	NULL
Lenardo	NULL
MJ	NULL
:	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Rel	NULL
:	NULL
Participants	NULL
in	NULL
a	NULL
multiform	NULL
transcriptional	NULL
regulatory	NULL
system	NULL
,	NULL
in	NULL
Jeon	NULL
KW	NULL
,	NULL
Fried-lander	NULL
M	NULL
,	NULL
Jarvik	NULL
J	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
International	NULL
Review	NULL
of	NULL
Cytology	NULL
.	NULL

San	NULL
Diego	NULL
,	NULL
CA	NULL
,	NULL
Academic	NULL
,	NULL
1993	NULL
,	NULL
p	NULL
1	NULL
23	NULL
.	NULL

Grimm	NULL
S	NULL
,	NULL
Bacuerle	NULL
PA	NULL
:	NULL
The	NULL
inducible	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
structure-function	NULL
relationship	NULL
of	NULL
its	NULL
protein	NULL
subunits	NULL
.	NULL

Biochem	NULL
J	NULL
290:297	NULL
,	NULL
1993	NULL
24	NULL
.	NULL

Ghosh	NULL
S	NULL
,	NULL
Gifford	NULL
AM	NULL
,	NULL
Riviere	NULL
LR	NULL
,	NULL
Tempst	NULL
P	NULL
,	NULL
Nolan	NULL
GP	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Cloning	NULL
of	NULL
the	NULL
p50	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
homology	NULL
to	NULL
re	NULL
?	NULL

and	NULL
dorsal	NULL
.	NULL

Cell	NULL
62:1019	NULL
,	NULL
1990	NULL
25	NULL
.	NULL

Ruben	NULL
SM	NULL
,	NULL
Dillon	NULL
PJ	NULL
,	NULL
Schreck	NULL
R	NULL
,	NULL
Henkel	NULL
T	NULL
,	NULL
Chen	NULL
C	NULL
,	NULL
Maher	NULL
M	NULL
,	NULL
Baeuerle	NULL
PA	NULL
,	NULL
Rosen	NULL
C	NULL
:	NULL
Isolation	NULL
of	NULL
a	NULL
rel-related	NULL
human	NULL
cDNA	NULL
that	NULL
potentially	NULL
enclodes	NULL
the	NULL
65-kD	NULL
subunit	NULL
of	NULL
NF-kB	NULL
.	NULL

Science	NULL
251:1490	NULL
,	NULL
1991	NULL
26	NULL
.	NULL

Brownell	NULL
E	NULL
,	NULL
Mittereder	NULL
N	NULL
,	NULL
Rice	NULL
NR	NULL
:	NULL
A	NULL
human	NULL
rel	NULL
proto-oncogene	NULL
cDNA	NULL
containing	NULL
an	NULL
Alu	NULL
fragment	NULL
as	NULL
a	NULL
potential	NULL
coding	NULL
exon	NULL
.	NULL

Oncogene	NULL
4:935	NULL
,	NULL
1989	NULL
27	NULL
.	NULL

Kunsch	NULL
C	NULL
,	NULL
Ruben	NULL
SM	NULL
,	NULL
Rosen	NULL
CA	NULL
:	NULL
Selection	NULL
of	NULL
optimal	NULL
«	NULL
B/	NULL
Rel	NULL
DNA-binding	NULL
motifs	NULL
:	NULL
Interaction	NULL
of	NULL
both	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
with	NULL
DNA	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
12:4412	NULL
,	NULL
1992	NULL
28	NULL
.	NULL

Liou	NULL
HC	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Regulation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

l	NULL
transcription	NULL
factor	NULL
and	NULL
IxB	NULL
inhibitor	NULL
system	NULL
.	NULL

Curr	NULL
Opin	NULL
Cell	NULL
Biol	NULL
5:477	NULL
,	NULL
1993	NULL
29	NULL
.	NULL

Famaey	NULL
JP	NULL
,	NULL
Paulus	NULL
HE	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Therapeutic	NULL
Applications	NULL
of	NULL
NSAID	NULL
's	NULL
Subpopulations	NULL
and	NULL
New	NULL
Formulations	NULL
.	NULL

New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
Dekker	NULL
,	NULL
1992	NULL
30	NULL
.	NULL

Brooks	NULL
PM	NULL
,	NULL
Kean	NULL
WF	NULL
,	NULL
Buchanan	NULL
WW	NULL
,	NULL
in	NULL
:	NULL
The	NULL
Clinical	NULL
Pharmacology	NULL
of	NULL
Anti-Inflammatory	NULL
Agents	NULL
.	NULL

Philadelphia	NULL
,	NULL
PA	NULL
,	NULL
Taylor	NULL
and	NULL
Francis	NULL
,	NULL
1986	NULL
,	NULL
p	NULL
32	NULL
31	NULL
.	NULL

Weissmann	NULL
G	NULL
:	NULL
Aspirin	NULL
.	NULL

Sci	NULL
Am	NULL
264:84	NULL
,	NULL
1991	NULL
32	NULL
.	NULL

Morris	NULL
HG	NULL
,	NULL
Sherman	NULL
NA	NULL
,	NULL
McQuain	NULL
C	NULL
,	NULL
Goldlust	NULL
MB	NULL
,	NULL
Chang	NULL
SF	NULL
,	NULL
Harrison	NULL
LI	NULL
:	NULL
Effects	NULL
of	NULL
salsalate	NULL
(	NULL
nonacetylated	NULL
salicylate	NULL
)	NULL
and	NULL
aspirin	NULL
on	NULL
serum	NULL
prostaglandins	NULL
in	NULL
humans	NULL
.	NULL

Ther	NULL
Drug	NULL
Monit	NULL
7:435	NULL
,	NULL
1985	NULL
33	NULL
.	NULL

Rainsford	NULL
KD	NULL
:	NULL
Aspirin	NULL
and	NULL
the	NULL
Salicylates	NULL
.	NULL

London	NULL
,	NULL
UK	NULL
,	NULL
But-tersworth	NULL
1984	NULL
34	NULL
.	NULL

Abramson	NULL
S	NULL
,	NULL
Korchak	NULL
H	NULL
,	NULL
Ludewig	NULL
R	NULL
,	NULL
Edelson	NULL
H	NULL
,	NULL
Haines	NULL
K	NULL
,	NULL
Levin	NULL
R	NULL
,	NULL
Herman	NULL
R	NULL
,	NULL
Rider	NULL
L	NULL
,	NULL
Kimmel	NULL
S	NULL
,	NULL
Weissman	NULL
G	NULL
:	NULL
Modes	NULL
of	NULL
action	NULL
of	NULL
aspirin-like	NULL
drugs	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
§2:7227	NULL
,	NULL
1985	NULL
OETH	NULL
AND	NULL
MACKMAN	NULL
35	NULL
.	NULL

Abramson	NULL
S	NULL
,	NULL
Weissmann	NULL
G	NULL
:	NULL
The	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
nonsteroidal	NULL
antiinflammatory	NULL
drugs	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
32:1	NULL
,	NULL
1989	NULL
36	NULL
.	NULL

Kopp	NULL
E	NULL
,	NULL
Ghosh	NULL
S	NULL
:	NULL
Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
sodium	NULL
salicylate	NULL
and	NULL
aspirin	NULL
.	NULL

Science	NULL
265:956	NULL
,	NULL
1994	NULL
37	NULL
.	NULL

Morrissey	NULL
JH	NULL
,	NULL
Fair	NULL
DS	NULL
,	NULL
Edgington	NULL
TS	NULL
:	NULL
Monoclonal	NULL
antibody	NULL
analysis	NULL
of	NULL
purified	NULL
and	NULL
cell-associated	NULL
tissue	NULL
factor	NULL
.	NULL

Thromb	NULL
Res	NULL
52:247	NULL
,	NULL
1988	NULL
38	NULL
.	NULL

Virca	NULL
GD	NULL
,	NULL
Northemann	NULL
W	NULL
,	NULL
Shiels	NULL
BR	NULL
,	NULL
Widera	NULL
G	NULL
,	NULL
Broome	NULL
S	NULL
:	NULL
Simplified	NULL
Northern	NULL
blot	NULL
hybridization	NULL
using	NULL
5	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
.	NULL

Biotechniques	NULL
8:370	NULL
,	NULL
1990	NULL
39	NULL
.	NULL

Morrissey	NULL
JH	NULL
,	NULL
Fakhrai	NULL
H	NULL
,	NULL
Edgington	NULL
TS	NULL
:	NULL
Molecular	NULL
cloning	NULL
of	NULL
the	NULL
cDNA	NULL
for	NULL
tissue	NULL
factor	NULL
,	NULL
the	NULL
cellular	NULL
receptor	NULL
for	NULL
the	NULL
initiation	NULL
of	NULL
the	NULL
coagulation	NULL
protease	NULL
cascade	NULL
.	NULL

Cell	NULL
50:129	NULL
,	NULL
1987	NULL
40	NULL
.	NULL

Brown	NULL
DA	NULL
,	NULL
Kondo	NULL
KL	NULL
,	NULL
Wong	NULL
SW	NULL
,	NULL
Diamond	NULL
DJ	NULL
:	NULL
Characterization	NULL
of	NULL
nuclear	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
interferon-gamma	NULL
promoter	NULL
in	NULL
quiescent	NULL
and	NULL
activated	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
Eur	NULL
J	NULL
Immunol	NULL
22:2419	NULL
,	NULL
1992	NULL
41	NULL
.	NULL

Cordle	NULL
SR	NULL
,	NULL
Donald	NULL
R	NULL
,	NULL
Read	NULL
MA	NULL
,	NULL
Hawiger	NULL
JJ	NULL
:	NULL
Lipopolysaccharide	NULL
induces	NULL
phosphorylation	NULL
of	NULL
MAD3	NULL
and	NULL
activation	NULL
of	NULL
c-Rel	NULL
and	NULL
related	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
in	NULL
human	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:11803	NULL
,	NULL
1993	NULL
42	NULL
.	NULL

Cao	NULL
X	NULL
,	NULL
Mahendran	NULL
R	NULL
,	NULL
Guy	NULL
GR	NULL
,	NULL
Tan	NULL
YH	NULL
:	NULL
Detection	NULL
and	NULL
characterization	NULL
of	NULL
cellular	NULL
EGR-1	NULL
binding	NULL
to	NULL
its	NULL
recognition	NULL
site	NULL
.	NULL

J	NULL
Bio	NULL
}	NULL
Chem	NULL
268:16949	NULL
,	NULL
1993	NULL
43	NULL
.	NULL

Madden	NULL
SL	NULL
,	NULL
Rauscher	NULL
FJI	NULL
:	NULL
Positive	NULL
and	NULL
negative	NULL
regulation	NULL
of	NULL
transcription	NULL
and	NULL
cell	NULL
growth	NULL
mediated	NULL
by	NULL
the	NULL
EGR	NULL
family	NULL
of	NULL
zinc-finger	NULL
gene	NULL
products	NULL
.	NULL

Ann	NULL
NY	NULL
Acad	NULL
Sci	NULL
684:75	NULL
,	NULL
1993	NULL
44	NULL
.	NULL

Miller	NULL
JM	NULL
,	NULL
Ziegler-Heitbrock	NULL
HWL	NULL
,	NULL
Baeuerle	NULL
PA	NULL
:	NULL
Nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
,	NULL
a	NULL
mediator	NULL
of	NULL
lipopolysaccharide	NULL
effects	NULL
.	NULL

Immunotbi-ology	NULL
187:233	NULL
,	NULL
1993	NULL
45	NULL
.	NULL

Mackman	NULL
N	NULL
:	NULL
Protease	NULL
inhibitors	NULL
block	NULL
lipopolysaccharide	NULL
induction	NULL
of	NULL
tissue	NULL
factor	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
by	NULL
preventing	NULL
activation	NULL
of	NULL
c-Rel/p65	NULL
heterodimers	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:26363	NULL
,	NULL
1994	NULL
46	NULL
.	NULL

Halushka	NULL
PV	NULL
,	NULL
Wise	NULL
WC	NULL
,	NULL
Cook	NULL
JA	NULL
:	NULL
Studies	NULL
on	NULL
the	NULL
beneficial	NULL
effects	NULL
of	NULL
aspirin	NULL
in	NULL
endotoxic	NULL
shock	NULL
.	NULL

Relationship	NULL
to	NULL
inhibition	NULL
of	NULL
arachidonic	NULL
acid	NULL
metabolism	NULL
.	NULL

Am	NULL
J	NULL
Med	NULL
74:91	NULL
,	NULL
1983	NULL
47	NULL
.	NULL

Rao	NULL
PS	NULL
,	NULL
Cavanagh	NULL
D	NULL
,	NULL
Gaston	NULL
LW	NULL
:	NULL
Endotoxic	NULL
shock	NULL
in	NULL
pri-mates	NULL
:	NULL
Effects	NULL
of	NULL
aspirin	NULL
and	NULL
dipyridamole	NULL
administration	NULL
.	NULL

Am	NULL
J	NULL
Obstet	NULL
Gynecol	NULL
140:914	NULL
,	NULL
1981	NULL
48	NULL
.	NULL

Schaper	NULL
V	NULL
,	NULL
Lueddeckens	NULL
G	NULL
,	NULL
Forster	NULL
W	NULL
,	NULL
Scheuch	NULL
DW	NULL
:	NULL
Inhibition	NULL
of	NULL
lipoxygenase	NULL
(	NULL
LOX	NULL
)	NULL
or	NULL
of	NULL
cyclooxygenase	NULL
(	NULL
COX	NULL
)	NULL
improves	NULL
survival	NULL
of	NULL
rats	NULL
in	NULL
endotoxin	NULL
shock	NULL
.	NULL

Biomed	NULL
Biochim	NULL
Acta	NULL
47:8282	NULL
,	NULL
1988	NULL
49	NULL
.	NULL

Haupt	NULL
MT	NULL
,	NULL
Jastremski	NULL
MS	NULL
,	NULL
Clemmer	NULL
TP	NULL
,	NULL
Metz	NULL
CA	NULL
,	NULL
Goris	NULL
GB	NULL
:	NULL
Effect	NULL
of	NULL
ibuprofen	NULL
in	NULL
patients	NULL
with	NULL
severe	NULL
sepsis	NULL
:	NULL
A	NULL
randomized	NULL
,	NULL
double-blind	NULL
,	NULL
multicenter	NULL
study	NULL
.	NULL

Crit	NULL
Care	NULL
Med	NULL
19:1339	NULL
,	NULL
1991	NULL
50	NULL
.	NULL

Coran	NULL
AG	NULL
,	NULL
Drangowski	NULL
RA	NULL
,	NULL
Paik	NULL
JJ	NULL
,	NULL
Remick	NULL
DG	NULL
:	NULL
Ibuprofen	NULL
intervention	NULL
in	NULL
canine	NULL
septic	NULL
shock	NULL
:	NULL
Reduction	NULL
of	NULL
pathophysiology	NULL
without	NULL
decreased	NULL
cytokines	NULL
.	NULL

J	NULL
Surg	NULL
Res	NULL
53:272	NULL
,	NULL
1992	NULL
51	NULL
.	NULL

Parrillo	NULL
JE	NULL
:	NULL
Pathogenetic	NULL
mechanisms	NULL
of	NULL
septic	NULL
shock	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
328:1471	NULL
,	NULL
1993	NULL
52	NULL
.	NULL

Parry	NULL
GCN	NULL
,	NULL
Mackman	NULL
N	NULL
:	NULL
A	NULL
set	NULL
of	NULL
inducible	NULL
genes	NULL
expressed	NULL
by	NULL
activated	NULL
human	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
contain	NULL
«	NULL
B-like	NULL
sites	NULL
that	NULL
specifically	NULL
bind	NULL
c-Rel-p65	NULL
heterodimers	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:20823	NULL
,	NULL
1994	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1995	NULL
86	NULL
:	NULL
4144-4152	NULL
Salicylates	NULL
inhibit	NULL
lipopolysaccharide-induced	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
tissue	NULL
factor	NULL
gene	NULL
in	NULL
human	NULL
monocytic	NULL
cells	NULL
P	NULL
Oeth	NULL
and	NULL
N	NULL
Mackman	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
©1004	NULL
@	NULL
207	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/86/11/4144.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

